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ABSTRACT 
 
NOVEL TARGETS FOR REDUCING NICOTINE WITHDRAWAL-INDUCED PHENOTYPES:  
CONTRIBUTION OF THE AMPK PATHWAY AND BDNF VAL66MET POLYMORPHISM 
 
 
Bridgin G. Lee 
Julie A. Blendy 
Smoking is the leading cause of preventable illness and death in the United States. 
Despite this, current pharmacological treatments for nicotine withdrawal remain partially 
effective and the abstinence rate remains low. The development of novel 
pharmacotherapies that can mediate the aversive symptoms of nicotine withdrawal will 
contribute to improved cessation outcomes. To this end, the studies in this dissertation 
had two objectives: one- to identify novel molecular pathways underlying nicotine 
withdrawal and two- to examine the contribution of genetic variants to withdrawal 
symptoms. To address the first objective we used functional genomic approaches 
(chromatin immunoprecipitation and whole genome sequencing (ChIP-Seq)) to identify 
pathways that are altered following withdrawal from nicotine. Through these means we 
identified the AMPK (AMP-activated protein kinase) signaling pathway as one such 
target. In addition, we demonstrated that the AMPK pathway is activated following 
chronic nicotine, an effect that is reversed by 24-hour withdrawal. Maintaining AMPK 
activation during withdrawal via the preclinical AMPK activator AICAR or the FDA 
approved diabetes drug metformin attenuated anxiety-like behavior during nicotine 
withdrawal in preclinical animal models. Further, the reduction in anxiety-like behavior 
was through a mechanism dependent on the AMPKα subunit within the hippocampus, as 
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determined by a genetic AMPKα loss-of function animal model. Metformin treatment 
also reversed withdrawal-induced deficits in contextual fear conditioning. In our final 
study we examined the contribution of genetic variants to the affective phenotypes of 
nicotine withdrawal. We utilized a BDNF knock-in mouse containing the BDNF 
Val66Met polymorphism to examine the effect of this single nucleotide polymorphism 
(SNP) on anxiety-like behavior following withdrawal. Using this model we found blunted 
anxiety-like behavior in mice homozygous for the SNP (BDNFMet/Met) following 
withdrawal. We also observed an increase in expression of the BDNF prodomain in 
BDNFMet/Met mice following nicotine withdrawal, highlighting the potential role of this 
ligand in mediating withdrawal behavior. Together, research from this dissertation 
provide the first evidence of a direct effect of AMPK modulation on behavior following 
nicotine withdrawal, and provides the first example of using a mouse genetic variant 
model to examine withdrawal behavior.  
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CHAPTER 1 
GENERAL INTRODUCTION 
I. Nicotine Addiction 
In the United States over 40 million adults and more than 3.5 million youths 
under the age of 18 smoke (CDC, 2014). Considered the number one cause of 
preventable death, smoking claims nearly half a million lives per year in the United 
States (U.S. HHS, 2014). In 1964, the first Surgeon General report entitled “Smoking and 
Health” formally established cigarette smoking as the cause of a multitude of diseases 
ranging from liver cancer to diabetes. However, despite a disease list that encompasses 
nearly every organ in the body it is estimated that at least 60,000 additional deaths per 
year are due to causes not yet formally recognized by the Surgeon General (Carter et al., 
2015), yet still attributable to smoking. 
Tobacco smoke contains approximately 4,700 different substances (Borgerding 
and Klus, 2005) including nicotine, the established addictive component of cigarettes 
(Stolerman and Jarvis, 1995). A naturally occurring chemical compound, nicotine (3-(1-
Methyl-2-pyrrolidinyl)pyridine), acts as an acute agonist at nicotinic acetylcholine 
receptors (nAChRs) located throughout the body including the central nervous system 
(CNS) (Holladay et al., 1997). Within the CNS nAChRs are located predominantly on 
presynaptic terminals (Wonnacott et al., 1996) and are composed of α and β subunits 
grouped into homopentamers (all α subunits) or heteropentamers (combination of α and β 
subunits). Similar to other drugs of abuse nicotine can activate the mesocorticolimbic 
dopamine reward system (Pontieri et al., 1996) and stimulates the release of almost all 
neurotransmitters (dopamine, serotonin, norepinephrine) (Markou, 2008). Activation of 
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these neurotransmitters produces reinforcing effects including mild euphoria, reduced 
negative mood and heightened arousal (Pomerleau and Pomerleau, 1992; Stolerman and 
Jarvis, 1995) that contribute to a physiological dependence and strengthening of the 
smoking habit. Chronic nicotine also contributes to multiple adaptive changes in the 
central nervous system including long-lasting changes in gene expression (Martin-Soelch, 
2013). These changes underlie the physiological withdrawal symptoms that accompany 
abstinence from nicotine. Aversive symptoms of nicotine withdrawal act as negative 
reinforcers encouraging smoking behavior to provide relief from the negative withdrawal 
symptoms (West et al., 2006). The reinforcing properties of nicotine, and the aversive 
effects of withdrawal both contribute to why nicotine dependence is considered a chronic, 
relapsing condition (Rennard and Daughton, 2014).  
 
II. Nicotine Withdrawal in Humans 
Nicotine withdrawal is characterized by a collection of somatic (physical), 
affective, and cognitive symptoms following an abrupt depletion of nicotine. Decreased 
heart rate and increased weight are somatic indicators of withdrawal while affective 
symptoms include increased irritability, anxiety, and depression (Hughes and Hatsukami, 
1986; Hughes, 1992; 2007a). Lastly, withdrawal induces cognitive deficits, specifically 
an inability to concentrate (Wesnes et al., 2013). These symptoms are important factors in 
both maintaining drug dependence and in the relapse that follows a quit attempt. 
Withdrawal symptoms emerge within hours of cessation (al’Absi et al., 2004; Hendricks 
et al., 2006) and follow a time-limited course of 2-4 weeks (Hughes, 1992; 2007a). 
Surveys of self-reported symptoms and cognitive performance assays allow for 
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quantitative analysis of qualitative symptom data. Studies using these methods have 
shown that the severity rating of experienced symptoms act as strong predictors of 
relapse (Piasecki et al., 1998; 2000), with greater withdrawal symptoms observed in those 
that relapse compared to those that successfully quit (al’Absi et al., 2004). Of mechanistic 
importance, withdrawal symptoms are a direct result of nicotine deprivation. Nicotine 
replacement therapy lessens the severity of withdrawal symptoms and increases 
abstinence rates (Schuurmans et al., 2004; Rose et al., 2006; Atzori et al., 2008). 
However, even with nicotine replacement therapy, or either of the two other FDA 
approved therapies for nicotine cessation (Chantix®, Zyban®), the rate of successful quit 
attempts remains low.  
Nicotine withdrawal symptoms in humans: Cognitive deficits The role of nicotine in 
enhancing attention and ameliorating cognitive deficits is seen across multiple diseases 
including Alzheimers (Sahakian et al., 1989), Parkinsons (Kelton et al., 2000), and 
attention deficit/hyperactivity disorder (ADHD) (Potter and Newhouse, 2008). Although 
the viability of nicotine as a cognitive enhancer is still debated, nicotine administration in 
a non-smoking, healthy population can provide cognitive benefits (Provost and 
Woodward, 1991; Jubelt et al., 2008). The perceived cognitive benefits of nicotine 
contribute to the maintenance of nicotine dependence, while the cognitive deficits 
induced by withdrawal from nicotine act as a barrier to quitting. 
Cognitive deficits are a commonly reported symptom of nicotine withdrawal, with 
66% self-reporting difficulty concentrating during days 1-3 post-cessation (Ward et al., 
2001). Signs of cognitive deficits emerge very quickly, within 2-3 hours post cigarette, 
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and peak at 24-hour withdrawal (Hendricks et al., 2006). Furthermore, cognitive 
performance during abstinence is inversely correlated with time to relapse (Patterson et 
al., 2010). Multiple studies support that nicotine deprivation causes impaired 
performance in sustained attention tasks, and arithmetic response time (Snyder and 
Henningfield, 1989; Provost and Woodward, 1991; Myers et al., 2007; Wesnes et al., 
2013). The effect of nicotine withdrawal on working memory however, remains unclear. 
Studies have demonstrated no effect of nicotine withdrawal on working memory (Myers 
et al., 2007; Sweet et al., 2010; Wesnes et al., 2013). In contrast, others have shown 
impaired working memory following nicotine withdrawal; including slower response and 
greater errors in a performance task of working memory (Mendrek et al., 2006). Re-
exposure to nicotine during withdrawal normalizes most withdrawal-induced deficits in a 
dose-dependent manner (Snyder and Henningfield, 1989; Bell et al., 1999; Atzori et al., 
2008). Not only is cognition improved with nicotine therapy post-cessation, but 
performance tasks such as arithmetic response time and logical reasoning are enhanced 
above baseline (smoking) measurements (Snyder and Henningfield, 1989; Myers et al., 
2007). 
Multiple variables could contribute to the differential effects of nicotine 
withdrawal on working memory, these include: sample size, subject variance in nicotine 
dependence, sex, genetics and length of abstinence prior to testing. Recent neuroimaging 
developments have allowed scientists a unique insight into the functional effect of 
nicotine withdrawal independent of behavioral manifestations. One such study found that 
following an overnight abstinence, more variation in the activation and deactivation 
profiles within the brain are seen compared to those that were given nicotine during 
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withdrawal, suggesting an overall change in neural processing (Sweet et al., 2010). 
Continued efforts in linking human brain activity to the cognitive symptoms of 
withdrawal will highlight areas of functional relevance for improved pharmacotherapies.  
Nicotine withdrawal symptoms in humans: Negative affect The subjective effects of 
nicotine administration include positive affect, as defined by feelings of comfort, 
satisfaction, and relaxation (Perkins et al., 2003). In contrast, following nicotine 
withdrawal negative affect including irritability, anxiety and depression, increases (see 
(Hughes, 2007a) for review). In addition to causing distress during cessation, negative 
affect experienced during withdrawal is prohibitive to a successful quit attempt, with 
variability in affect scores directly correlating to withdrawal-related outcomes (Piasecki 
et al., 1998; 2000). The occurrence of a relapse event is especially influenced by affective 
symptoms; with negative affect both precipitating and aggravating withdrawal attempts 
(Shiffman, 1982; Brandon et al., 1990). 
One characteristic of negative affect that is intensified and frequently reported 
following nicotine withdrawal is anxiety (Shiffman, 1982; Ward et al., 2001). Increased 
anxiety symptoms are experienced within 2-hours of quitting smoking (Hendricks et al., 
2006), and are most prevalent in the first three days post-cessation (Hughes et al., 1992; 
Gilbert et al., 1998; Ward et al., 2001). As the cessation expectancies of most smokers are 
focused on the immediate consequences of their quitting (Hendricks et al., 2009) putative 
factors such as anxiety that manifest quickly can greatly impact quit rates and contribute 
to relapse. Proceeding a lapse (temporary return to nicotine use), six in ten report 
negative affect, with those experiencing anxiety/tension progressing more quickly to a 
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complete relapse (full return to regular nicotine use) (Brandon et al., 1990). As a high 
prevalence of tobacco use is observed in those with mental illness, including anxiety 
disorders (Ziedonis et al., 2008), it is important to identify if withdrawal symptoms are 
due to a predisposed psychopathology. In contrast, twin studies have shown withdrawal-
induced symptoms, including anxiety, occur independently of any predisposition to 
mental or behavioral disorders thus supporting anxiety as a true pharmacological 
withdrawal symptom (Edwards and Kendler, 2011).   
 
III. FDA Approved Therapies for Nicotine Withdrawal 
In order to develop novel and improved pharmacotherapies for nicotine cessation 
it is critical to first understand the efficacy of current approved therapies in alleviating 
withdrawal symptoms including negative affect and cognitive deficits. At this time, there 
are three FDA-approved pharmacotherapies for nicotine withdrawal: nicotine 
replacement therapy, partial nAChR agonist varenicline (Chantix®), and the 
antidepressant bupropion (Zyban®). Previous meta-analysis demonstrated all therapies to 
be more efficacious in promoting smoking cessation than placebo with an odds ratio of 
2.1 and 2.5 for bupropion and varenicline respectively, and a range of 1.6 to 2.3 
according to the product for nicotine replacement therapy. Improvement of withdrawal 
symptom severity has also been demonstrated across all treatment groups (Jorenby et al., 
1999). However, even with pharmacological treatment one-year after a quit attempt, two 
in three people will lapse, and one in five people will return to smoking (Ucar et al., 
2014).  
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Nicotine replacement therapies Nicotine replacement therapy (NRT) uses remedial 
administration of nicotine as a treatment for smoking cessation. First investigated with 
2mg nicotine gum in 1984, there are currently five different types of nicotine replacement 
therapies approved by the FDA: nasal spray, inhaler, lozenge, patch, and gum. All 
nicotine replacement therapies, with the exception of inhalers and nasal spray are 
available over the counter and without a prescription. As most withdrawal symptoms are 
present within the first month after cessation, the efficacy of NRT in reducing symptoms 
within this time-point is significant. NRT reduces anxiety over the first month of 
treatment and abrogates difficulty concentrating throughout the first week (Jorenby et al., 
1996). Meta-analysis of 12 NRT trials confirmed it to be more efficacious than placebo 
for smoking cessation (Etter and Stapleton, 2006) with a one-year average relapse rate of 
30%. 
Bupropion The drug bupropion acts as a weak norepinephrine and dopamine reuptake 
inhibitor (Ascher et al., 1995). In addition to its effects within the synapse, bupropion is 
also a noncompetitive antagonist at α4β2 nicotinic receptors (Slemmer et al., 2000; 
Damaj et al., 2004). Initially FDA-approved for the treatment of depression, the first 
landmark clinical trial with bupropion as a treatment for smoking cessation occurred in 
1997 (Hurt et al., 1997). This trial demonstrated that the cessation rates at six-weeks and 
one-year were two times greater with bupropion treatment compared with placebo. In 
addition to maintaining cessation, bupropion treatment also increased the median time to 
relapse from 65 days to 156 days, a 140% increase over placebo (Hays et al., 2001). On 
top of reducing negative affect (West et al., 2008) bupropion improved working memory 
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and enhanced response time for number stimuli in a sustained attention task following an 
overnight abstinence period (Perkins et al., 2013). Despite its efficacy over placebo, the 
one-year abstinence rate with bupropion remains at 30% (Hays et al., 2001). 
Varenicline The drug varenicline is the current gold standard of smoking cessation 
therapies and is considered to be the most effective pharmacological treatment for short 
and long-term smoking cessation. A nicotine mimicker, varenicline stimulates nAChRs 
through its actions as a partial agonist at α4β2 and full agonist at α7 nAChRs (Mihalak et 
al., 2006). In addition, varenicline contributes to cessation maintenance through its 
actions as a nicotinic antagonist. As 88% of those who smoke a single cigarette during 
withdrawal eventually return to regular nicotine use (Brandon et al., 1990), blocking 
nicotine reward during an initial post-cessation lapse is a critical component to 
varenicline therapy.  
The efficacy of varenicline in smoking cessation was initially confirmed in 2006 
by two Phase III efficacy trials (Gonzales et al., 2006; Jorenby et al., 2006). Each trial 
independently corroborated the efficacy of varenicline over placebo and bupropion in 
maintaining abstinence. Varenicline reduced craving and negative affect and mitigated 
the rewarding effect of nicotine during a lapse (West et al., 2008). Varenicline also 
enhanced both sustained attention and working memory within 72-hours of withdrawal 
(Patterson et al., 2009). From the time when these trials were conducted, varenicline 
received the FDA’s strongest safety warning, a black box warning. The black box 
warning highlighted the risk of neuropsychiatric events associated with varenicline 
treatment including suicidal thoughts and aggressive or irrational behavior. In 2011 the 
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FDA added cardiovascular problems to its black box warning. Despite of these warnings, 
in 2014 varenicline was included in the IMS Health List of Top 100 Performing Drugs, 
with over two million prescriptions between October 2013 and September 2014. 
Notwithstanding safety and efficacy, varenicline treatment still demonstrates an overall 
smoking cessation rate of 32% after 1 year (Ucar et al., 2014), a rate comparable to other 
FDA-approved smoking cessation treatments. 
Combination therapies In addition to monotherapies, studies have also investigated the 
use of combination therapies in maintaining nicotine cessation and preventing relapse. 
Polytherapy with bupropion and nicotine patch compared to nicotine patch treatment 
alone increased abstinence rates (Jorenby et al., 1999). Polytherapy with varenicline also 
improved cessation with a higher abstinence rate at six months observed with co-
treatment of nicotine patch plus varenicline compared to varenicline treatment alone 
(Koegelenberg et al., 2014). Finally, subjects treated with a combination therapy of 
varenicline and bupropion compared to varenicline alone exhibited prolonged abstinence, 
however, this effect was lost after one-year (Ebbert et al., 2014). 
 
IV. Genetic Contribution to Withdrawal Variability 
Not all subjects respond equally to nicotine cessation treatment. Therefore, in 
addition to understanding the kinetics and mechanisms of current treatments it is equally 
as important to understand the contributions of ones genetic makeup to nicotine 
cessation. The importance of genetic influence on withdrawal is two-fold; one, it can 
predict the scale and diversity of precipitated withdrawal symptoms and two, it can 
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predict treatment response, thereby guiding the selection of pharmacotherapies. Genetic 
variability accounts for approximately 70% of the risk for nicotine dependence (Sullivan 
and Kendler, 1999; Vink et al., 2005). The severity of nicotine withdrawal and the ability 
to achieve and maintain abstinence are also both under considerable genetic control. A 
male twin study found a 31% genetic contribution to the variance of experienced nicotine 
withdrawal symptoms and a 51% genetic contribution to the variance in failed cessation 
(Xian et al., 2003). This finding was replicated and broadened to include a data set of 
female twins which found a 50% genetic contribution to smoking cessation, suggesting 
the influence of genes on withdrawal is independent of sex (Broms et al., 2006).  
The exact mechanism for how genetic variance contributes to phenotypic variance 
in nicotine withdrawal continues to be investigated through large-scale genome-wide 
association studies (GWAS) and directed single candidate gene approaches. Of specific 
focus is the contribution of single nucleotide polymorphisms (SNPs) to withdrawal from 
nicotine. SNP variants can predict cessation success (Sarginson et al., 2011), time to 
relapse  (King et al., 2012), and contribute to withdrawal symptoms (Kubota et al., 2006).  
These large association studies can also be used to narrow down the study to single genes 
of interest. A meta-analysis of 17 twin studies from the literature identified an association 
between brain-derived neurotrophic factor (BDNF) variants and nicotine dependence (Li, 
2006). Of particular interest to nicotine dependence and withdrawal is the BDNF genetic 
variant Val66Met. This variant is a non-synonymous SNP in the prodomain of the BDNF 
gene that substitutes a valine (val) for a methionine (met) amino acid (Val66Met). The 
BDNF Val66Met SNP is associated with more frequent smoking behavior in humans 
(Lang et al., 2007) and earlier smoking initiation (Zhang et al., 2012). This SNP can also 
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affect cessation and is associated with an increased percent of successful quitting 
(Breetvelt et al., 2012). Mice with the SNP on both alleles (BDNFMet/Met) exhibit 
increased anxiety-like behavior and cognitive deficits (Chen et al., 2006), behaviors 
central to nicotine withdrawal symptoms. These studies suggest a critical link between 
BDNF genetic variants, smoking and withdrawal. 
Of additional interest, studies have also shown a correlation between SNP variants 
and cessation drug efficacy. Variants in nicotinic receptor subtypes can predict response 
to varenicline, while variants within the drug-metabolizing enzyme CYP2B6 are 
associated with bupropion response (King et al., 2012). However, with over 4500 unique 
SNPs identified in a comparison of unsuccessful versus successful abstainers (Uhl et al., 
2008) there still remains much research in the area of individual SNP variant contribution 
to nicotine withdrawal. 
 
V. Preclinical Animal Models of Nicotine Withdrawal 
The use of animal models in investigating nicotine withdrawal allows for the 
opportunity to parse apart the specific genetic, behavioral, and molecular components 
contributing to the withdrawal syndrome observed in humans. Valid preclinical models of 
withdrawal have predictive validity and reliability that can be related back to human 
withdrawal symptoms and controlled within a laboratory setting. Furthermore, 
pharmacological and genetic manipulation of animal models allows researchers to probe 
at potential targets for novel pharmacotherapies and determine how to maximize the 
benefit of current therapies. Therefore, animal models of nicotine withdrawal can act both 
as a screening test for the development of novel cessation pharmacotherapies and as a 
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simulation of the behaviors that contribute to relapse in humans during withdrawal. 
Following both spontaneous and precipitated withdrawal with a nicotinic antagonist, 
mecamylamine, rodents exhibit the full spectrum of withdrawal symptoms. These 
symptoms mirror those of humans and include increased anxiety-like behavior and 
cognitive deficits as measured by difficult learning (Damaj et al., 2003; Davis et al., 
2005). In addition, rodents also exhibit physical (somatic) signs of withdrawal including 
increased paw and body tremors (Damaj et al., 2003). However, these physical signs are 
not similar to those in humans (Hughes, 2007b), and do not contribute to drug motivation 
or withdrawal adversity as significantly as negative affect and cognition (Baker et al., 
2004). 
Behavioral animal models of nicotine withdrawal: Negative affect In order to model 
affective symptoms of withdrawal, behavioral assays that examine anxiety-like behavior 
in rodents can be used. These assays include: the novelty-induced hypophagia (NIH) test, 
marble-burying (MB), open field test (OFT), and the elevated zero maze (EZM). The 
NIH test is a sensitive and dependable test for anxiety-like behavior in rodents. In this test 
an animal is trained to consume a palatable food in their home cage. For testing day, mice 
are placed in a novel environment under anxiety-inducing conditions including bright 
light, no bedding, and/or aversive scent. Increased latency to approach and eat the 
palatable food on testing day, in such an aversive environment, is a direct measure of 
increased anxiety-like behavior. Pharmacological anxiolytics ameliorate the anxiogenic 
effect of the novel environment, while drugs with no known anxiolytic capabilities have 
no effect (Merali et al., 2003; Bechtholt et al., 2008), highlighting the specificity of this 
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test for anxiety behavior. Of importance, this test mimics the effects of nicotine and 
withdrawal from nicotine in humans with decreased latency (decreased anxiety-like 
behavior; anxiolytic) observed following chronic nicotine treatment, and increased 
latency (increased anxiety-like behavior; anxiogenic) observed following 24-hour 
withdrawal in mice (Turner et al., 2013). 
The marble-burying test is a second preclinical model used to screen anxiolytics. 
In this test, mice are placed in a cage full of bedding with marbles lain on top. Unlike the 
passive measurements used in the NIH (latency to approach), MB uses the active 
measurement of burying to quantify anxiety-like behavior. Although the marbles 
represent a novel object they are not aversive to mice as illustrated by equal preference 
shown for a compartment with and without marbles (Njung'e and Handley, 1991). The 
use of this paradigm in combination with the NIH test provides a nice complementary 
measure of anxiety-like behavior both in the absence and presence of aversive 
environments, thus controlling for this potential stressor on behavior. This test is specific 
to known anxiolytics including alprazolam, diazepam and chlordiazepoxide, with all 
anxiolytics significantly reducing the number of marbles buried (Broekkamp et al., 1986; 
Nicolas et al., 2006). Of importance to withdrawal modeling, acute nicotine decreases the 
number of marbles buried (decreased anxiety-like behavior; anxiolytic) while 24-hour 
withdrawal from nicotine increases the number of marbles buried (increased anxiety-like 
behavior; anxiogenic) (Turner et al., 2010). In addition to anxiolytics, the responsiveness 
of the MB test to cessation pharmacotherapies increases its translational value, with acute 
varenicline abrogating the observed increase in marbles buried during withdrawal from 
nicotine (Turner et al., 2013). 
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Behavioral animal models of nicotine withdrawal: Cognition The cognitive deficits 
observed in humans during withdrawal from nicotine can be modeled in preclinical 
rodent models. In order to model these deficits behavioral assays that examine learning 
and memory in rodents can be used. These assays include: Fear conditioning (FC), 
Morris Water Maze (MWM), and Novel Object Recognition (NOR).  
 Fear conditioning is a test of learning and memory where an animal is trained 
with two paired stimuli: a conditional stimulus (white noise) to an unconditional stimulus 
(foot shock). In order to assess how withdrawal from nicotine specifically affects 
cognition in this task, training in rodents occurs during the withdrawal time point. 
Twenty-four hours following training mice are placed back in the same environment they 
were trained in and freezing behavior for contextual fear conditioning is measured in the 
absence of any stimuli. Following this contextual test, the rodent is tested again in a novel 
environment with and without the presence of the conditioned stimuli (white noise). This 
second test is a measure of any deficits or enhancements in cued learning. Increased 
freezing behavior in either the context or cued test is interpreted as enhanced cognition, 
while decreased freezing behavior can be interpreted as a cognitive deficit.  
Nicotine dose dependently enhances contextual FC in mice (Gould and Stephen 
Higgins, 2003) and this enhancement is dependent on the hippocampus, a brain region 
critical to learning and memory (Davis and Gould, 2009). Similar to humans, following 
withdrawal from nicotine cognitive deficits, as measured by a decrease in freezing 
behavior, are observed in contextual but not cued learning (Davis et al., 2005; Davis and 
Gould, 2009). This deficit can be reversed with acute administration of nicotine, 
suggesting that the observed learning is specific to a withdrawal state. Also similar to 
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what is clinically detected, nicotine administration during withdrawal not only 
ameliorates the cognitive deficits associated with withdrawal, but enhances them above 
baseline levels (Snyder and Henningfield, 1989; Davis et al., 2005; Myers et al., 2007). 
FC is also a test sensitive to the effects of nicotine cessation therapies. Bupropion 
(Portugal and Gould, 2007) and varenicline (Raybuck et al., 2008) dose-dependently 
ameliorate the contextual fear conditioning deficits observed in mice following 
withdrawal from nicotine. Therefore, the FC paradigm offers two advantages: one, 
demonstration of cognitive withdrawal symptomology and two, modeling of cessation 
treatment efficacy for the cognitive deficits observed during withdrawal. 
 
VI. Drug Repositioning for the Discovery of Novel Nicotine Cessation Therapies 
In addition to using animal models in the discovery of novel therapeutics, these 
models can also identify current FDA-approved drugs that might be efficacious outside of 
their originally approved medical indication (repurposed) for nicotine cessation. There 
are multiple benefits to repurposing medications including: established safety and 
efficacy, decreased development costs and shorter time to approval. Novel drug 
development is not only financially prohibitive, standing at $2.6 billion according to a 
recent report by the Tufts Center for the Study of Drug Development, but also risky with 
a ~16% success rate for clinical approval (DiMasi, 2014). Utilizing established profiles of 
approved drugs including toxicology, pharmacokinetics and manufacturing data, up to 
40% of development costs (Chong and Sullivan, 2007) and several years of development 
time (Ashburn and Thor, 2004) can be saved through repurposing. 
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Repurposing is not a novel concept to nicotine cessation drug development. The 
FDA-approved drug bupropion was initially approved for use in a depressed population. 
However, anecdotal evidence demonstrated that those who were taking bupropion for 
depression exhibited greater spontaneous smoking cessation during treatment, leading to 
its development as a smoking cessation aid (Hurt et al., 1997). In addition to bupropion, 
there are multiple open clinical trials investigating the use of FDA-approved drugs for 
smoking cessation (Table 1.1). These drugs have primary indications ranging from the 
treatment of high blood pressure, to tuberculosis, to sleep disorder therapy. However, 
they all share a common link in showing preclinical promise as nicotine cessation 
therapies.  
        
VII. AMPK Activation as a Repositioning Candidate for Nicotine Cessation 
Shared pathophysiology across disease states can contribute to the identification 
of common therapeutic targets and thus shared pharmacotherapies. Mei and colleagues 
demonstrated how network modeling can identify gene and/or molecule clusters involved 
!
Table 1.1 Ongoing clinical trials for repurposing FDA-approved drugs in smoking cessation !!!!!!!!!!!!
 
 
HMG, 3-hydroxy-3-methyl-glutaryl; SNRI, serotonin-norepinephrine reuptake inhibitor; NMDA, N-methyl-D-aspartate 
Drug Sponsor Primary Indication Drug Type Phase 
Simvastatin Poitiers University Hospital Dyslipidemia HMG CoA reductase inhibitor II 
Guanfacine Yale University Hypertension Alpha-2 adrenergic receptor agonist II 
Carvedilol Yale University Hyptertension Beta-and alpha adrenergic receptor blocker II 
Levomilnacipran University of Minnesota Depression SNRI N/A 
D-cycloserine University of Texas at Austin Tuberculosis 
Broad spectrum antibiotic, 
partial NMDA receptor agonist 0 
Galantamine University of Pennsylvania 
Alzheimers 
Disease Acetylcholinesterase inhibitor II 
Ramelteon University of Pennsylvania Insomnia Melatonin receptor agonist II 
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in not only one, but across multiple CNS diseases, allowing for discovery of shared 
pathways for repurposing opportunities (Mei et al., 2012). Our lab utilized a similar 
network pathway analysis and discovered that the “cell-cell signaling, carbohydrate 
metabolism, lipid metabolism” pathway was altered following nicotine withdrawal. We 
determined that the central mediator of this pathway was the molecule adenosine 
monophosphate-activated protein kinase (AMPK), and that the pathway was already an 
established target for diabetes treatment. Therefore, we hypothesized that one FDA-
approved drug that could be a safe and efficacious treatment for smoking cessation is the 
diabetes drug and AMPK activator, metformin. Although metformin has not yet been 
used in clinical trials, its preclinical profile includes alterations in cognition and negative 
affect. These findings suggest that AMPK activation, specifically with metformin, could 
be a novel new pharmacotherapy for smoking cessation.   
AMP-Activated Protein Kinase (AMPK) AMPK is a serine/threonine kinase with a 
critical role as a metabolic regulator within the body (Moore et al., 1991). First 
characterized within the liver, AMPK is present within multiple tissues including the 
brain, where it can play a role in neuroplasticity (Potter and Newhouse, 2008), energy 
balance (Kim et al., 2004; Landree et al., 2004), and neuroprotection (Kuramoto et al., 
2007). AMPK is a heterotrimeric protein consisting of one catalytic α subunit (α1, α2), 
and two non-catalytic β (β1, β2) and γ (γ1, γ2) subunits, all three of which are required 
for the functional integrity of the kinase (Woods et al., 1996). While both the α1 and α2 
catalytic subunits are expressed within neurons, the α2 subunit predominates (Turnley et 
al., 1999; Culmsee et al., 2001). All other subunit isoforms, with the exception of γ2, are 
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expressed in the brain (Turnley et al., 1999). However, the specific role of each isoform 
within the brain remains to be determined.  
 AMPK is a master regulator of cellular metabolism. As such, multiple systems 
converge on AMPK to activate it via phosphorylation at threonine (Thr) 172 including 
the kinases Ca2+/calmodulin-dependent protein kinase kinase-β (CamKKβ) (Woods et al., 
2005) and Liver kinase B1 (LKB1) (Woods et al., 2003), as well as the hormone 
adiponectin (Kubota et al., 2007). Prior to the development of pharmacological activators 
ATP depletion via fructose or environmental stressors such as heat shock or arsenite were 
used to stimulate AMPK activation. However, as these conditions introduced a variety of 
uncontrolled variables the utilization of pharmacological compounds to specifically 
activate AMPK led to more control and greater characterization of the AMPK pathway. 
AMPK can be activated by two pharmacological compounds; 5-Aminoimidazole-4-
carboxamide ribonucleoside (AICAR) and the FDA-approved drug metformin.  
AICAR is an AMPK activator used for preclinical in vitro and in vivo 
experiments. Once mono-phosphorylated, AICAR mimics AMP and acts as an allosteric 
activator of AMPK. Additionally, and of experimental importance, AICAR specifically 
activates AMPK without altering levels of ATP, ADP, or AMP (Corton et al., 1995). Of 
specific importance to CNS research AICAR can cross the blood brain barrier. However, 
large doses are needed as its brain permeability is greatly limited (Marangos et al., 1990).  
In addition to the preclinical AMPK activator AICAR an additional 
pharmacological compound that is used clinically is metformin. Metformin is a first-line 
therapy for the treatment of type 2 diabetes, acting to reduce hyperglycemia and improve 
insulin sensitivity. Metformin is a well-tolerated drug with an established record of safety 
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and efficacy (Charles, 1997). Even 65 years after its approval, metformin is still 
recommended as an initial pharmacotherapy for type 2 diabetes due to its low cost, 
breadth of patient data, and ability to lower blood glucose without causing hypoglycemia 
(Bolen et al., 2007).  
Metformin is a potent indirect activator of AMPK, acting to inhibit complex I of 
mitochondrial oxidative phosphorylation resulting in decreased ATP and subsequent 
activation of AMPK (El-Mir et al., 2000). Metformin can also activate AMPK through 
phosphorylation of the Thr172 site on the catalytic (α) subunit of AMPK, independent of 
changes in the ADP:ATP ratio (Hawley et al., 2002). Although evident that metformin 
can effectively activate AMPK, the role of AMPK in mediating the physiological effects 
of metformin remains controversial. Metformin exhibits both AMPK-dependent (Cao et 
al., 2014a) actions as well as AMPK-independent actions, as demonstrated by its ability 
to mediate glucose production in the absence of AMPK in the liver (Foretz et al., 2010). 
Due to its ability to rapidly cross the blood brain barrier metformin is being investigated 
in preclinical mouse models for multiple CNS indications including Alzheimer’s disease 
(Du et al., 2014), Huntington’s (Ma et al., 2007) and multiple sclerosis (Nath et al., 
2009).  
Role of AMPK on cognition in animals Of importance to nicotine withdrawal is the 
ability of AMPK to abrogate cognitive deficits. AMPK promotes neurogenesis and is a 
direct modulator of long-term potentiation, a measure of synaptic strength critical to 
learning and memory (Wang et al., 2012). Further, research in mice and rats supports the 
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role of AMPK in cognition, specifically in hippocampal-dependent spatial memory and 
cognitive mapping tasks including the Morris water maze, radial arm maze and T-maze. 
The majority of research on AMPK in cognitive performance is focused on the 
role of AMPK activators in preventing or reversing cognitive deficits generated by 
pharmacological or diet-induced disease models (Table 1.2). Metformin protected against 
cognitive impairments induced by pentylenetetrazole in a seizure model (Zhao et al., 
2014), and restored cognitive impairments following diabetic stroke (Prakash et al., 
2013). AICAR showed similar cognitive protection in a streptozotocin-induced model of 
Alzheimer’s disease (Du et al., 2014). The effects of AMPK activation following high-fat 
diet remain less clear. Metformin reversed memory impairments caused by 12-weeks of 
high-fat diet (Pintana et al., 2012). Yet others show that metformin had no effect on 
cognition following a high-fat diet (McNeilly et al., 2012; Lennox et al., 2014). The 
mode of administration, length of metformin treatment and length of diet all varied 
between studies.  
In wildtype animals metformin can enhance spatial memory formation (Wang et 
al., 2012). In contrast, the effect of AICAR on cognitive enhancement is dependent on 
rodent age (Kobilo et al., 2014), drug concentration (Dagon et al., 2005), mode of 
administration (Dash et al., 2006) and length of treatment (Kobilo et al., 2011). 
Contingent on these factors AICAR can impair, enhance, or have no effect on cognitive 
performance. The alternating effects of AMPK activation on cognition highlight a need 
for additional research in this arena, independent and dependent of disease state.  
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Role of AMPK on negative affect in animals The role of AMPK in negative affect, 
specifically anxiety-like behavior is not well characterized (Table 1.2). In rats, the stress 
hormone corticosterone can modulate AMPK activity (Christ-Crain et al., 2008) and 
glucocorticoid receptor expression can be modified by metformin treatment (Cleasby et 
al., 2003). Both steroid and receptor play an important role in mechanisms underlying 
anxiety-like behavior. Therefore, understanding the effect of AMPK on behaviors 
modulated by this system is critical. Similar to cognition, the effects of AMPK activators 
on anxiety-like behavior have primarily been examined in preclinical disease models. 
Metformin pretreatment decreased anxiety-like behavior as measured by the elevated plus 
maze in a preclinical model of global ischemia (Sarkaki et al., 2015) and a global model 
of co-occurring diabetes and stress (Garabadu and Krishnamurthy, 2014). Following a 
stressor such as chronic unpredictable stress, pAMPKα is reduced ~50%. This decrease in 
phosphorylation is correlated with increased anxiety-like behavior in the open field test, 
elevated plus maze, and novelty suppressed feeding test (Zhu et al., 2014). No studies to 
date have examined the effect of AMPK activators on anxiety-like behavior in naïve 
animals.  
	  
	  
22	  
 
VIII. Overview of Dissertation 
 In support of the established role of nicotine withdrawal symptoms in predicting 
relapse and the utility of preclinical models for withdrawal, the goal of this dissertation 
was twofold– to utilize both a pharmacological and genetic approach to examine the 
mechanisms of withdrawal-induced phenotypes. The kinase AMPK was identified as a 
novel target altered during withdrawal from nicotine in Chapter 2. We found AMPK to 
be increased following chronic nicotine, while this activation was lost 24-hours following 
withdrawal. Maintaining activation of AMPK during withdrawal via two 
 
Table 1.2. Effect of AMPK activation on affective behavior and cognitive performance in vivo 
 
AICAR, 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside; MWM, morris water maze; RAM, radial arm maze; NOR, novel object 
recognition; MTP/NMTP, matching and non-matching to position task; EPM, elevated zero maze; OFT, open field test; AD, Alzheimer’s 
disease; HFD, high-fat diet; T2DM, type 2 diabetes mellitus 
Cognitive Mouse AICAR 500 mg/kg (i.p.) for 3-14 days MWM 
In young mice 3 days improved 
performance. In aged mice 14 
days improved performance 
Kobilo et 
al., 2014 
 Mouse AICAR 25 nM (i.p.) or 1-2 mM (i.p.) for 10 days RAM 
25nM improved performance and 
1-2 mM deteriorated performance 
in calorie-restricted mice 
Dagon et 
al., 2005 
 Mouse AICAR 
500 mg/kg (i.p.) for 7-14 
days, administered 2-weeks 
prior to testing 
MWM 
7 days of treatment enhanced 
performance, 14 day treatment 
had no effect 
Kobilo et 
al., 2011 
 Rat AICAR 260 ng (intrahippocampal) MWM Impaired memory formation and performance 
Dash et 
al., 2006 
 Rat AICAR 50 μg (i.c.v. injection), 6-weeks prior to testing MWM 
Protected against cognitive 
impairments in an AD model 
Du et al., 
2015 
 Mouse Metformin 300 mg/kg (in drinking water) for 20 days NOR No effect on NOR following HFD 
Lennox et 
al., 2014 
 Rat Metformin 144 mg/kg (in diet) for 10-weeks 
MTP 
NMTP No effect alone or after HFD 
McNeilly et 
al., 2012 
 Mouse Metformin 200 mg/kg (i.p.), every other day over 28 days MWM 
Protected against seizure-induced 
cognitive impairments, no effect in 
naïve mice. 
Zhao et 
al., 2014 
 Mouse Metformin 200 mg/kg (i.p.) for 38 days MWM Enhanced ability to update spatial memory in MWM probe test 
Wang et 
al., 2012 
 Rat Metformin 15 mg/kg (gavage) 2x/day for 21 days MWM 
Reversed impairments caused by 
12-week HFD 
Pintana et 
al., 2012 
 Rat Metformin 300 mg/kg (in drinking water) for 14 days NOR 
Restored impairments caused by 
diabetic stroke 
Prakash et 
al., 2013 
Affective Mouse Metformin 200 mg/kg for 14 days EPM  
Decreased anxiety-like behavior, 
increased exploratory behavior in 
a model of cerebral ischemia 
Sarkaki et 
al., 2015 
 Rat Metformin 25 mg/kg (gavage) for 7 days EPM 
Ameliorated anxiogenic behavior 
generated by co-occurring T2DM 
and stress condition  
Garabadu 
et al, 2014 
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pharmacological activators, AICAR and metformin alleviated anxiety-like behavior and 
rescued the cognitive deficits observed in preclinical models of nicotine withdrawal. 
Furthermore, i.c.v. and AAV studies found the efficacy of metformin in alleviating 
withdrawal symptoms to be dependent on activation of the catalytic AMPKα subunit 
within the hippocampus. In Chapter 3, we utilized a mouse model of a human genetic 
variant in the BDNF gene, the Val66Met single nucleotide polymorphism (SNP). Using 
this model we investigated the effect of this polymorphism in mediating the anxiety-like 
behavior following withdrawal from nicotine. Our findings showed a reduced withdrawal 
phenotype in mice with the BDNFMet/Met genotype. Together, these studies support the 
clinical AMPK activator metformin as a novel treatment for smoking cessation and 
demonstrate the utility of mouse SNP models in identifying molecular markers for 
withdrawal sensitivity in humans. Ultimately these findings could contribute to a novel 
pharmacotherapy and further the understanding of personalized medicine for the 
symptoms of nicotine withdrawal. An overall discussion of this body of work along with 
questions remaining and future directions are included in Chapter 4.  
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Abstract 
Cigarette smoking is the leading cause of preventable disease and death in the United 
States, with more persons dying from nicotine use than from any other addiction. 
Cessation from smoking incurs multiple health benefits. However, even with current 
smoking cessation medications the abstinence rate remains low. In order to identify novel 
molecular targets for development of new smoking cessation therapies we employed 
functional genomic approaches (chromatin immunoprecipitation and whole genome 
sequencing (ChIP-Seq)) to identify pathways that are altered following withdrawal from 
nicotine. Using ChIP-Seq for CREB in the hippocampus we identified the AMPK (AMP-
activated protein kinase) signaling pathway as one such target. Here we demonstrate that 
the AMPK pathway is activated following chronic nicotine exposure, an effect that is 
reversed by 24-hour withdrawal from nicotine. We use a combination of pharmacological 
and genetic approaches to modulate the AMPK pathway during nicotine withdrawal. We 
find that increasing pAMPK levels, and consequently downstream AMPK signaling, 
attenuates anxiety-like behavior following nicotine withdrawal in two behavioral 
paradigms, novelty-induced hypophagia and marble burying. Furthermore, we show that 
the FDA approved drug metformin - an AMPK activator – reduces withdrawal induced 
anxiety-like behavior through a mechanism dependent on the AMPKα subunit within the 
hippocampus. Further, chronic metformin treatment also reversed withdrawal-induced 
deficits in contextual fear conditioning. These studies provide the first evidence of a 
direct effect of AMPK modulation on behavior following nicotine withdrawal, and 
highlight the potential repurposing of metformin and related compounds as a novel 
therapeutic target for smoking cessation.  
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Introduction 
Cigarette smoking constitutes a major health burden in the US, with smoking 
accounting for over 500,000 deaths a year nationwide (U.S. HHS, 2014). Despite over 30 
reports issued by the Surgeon General addressing the negative impact of smoking on the 
health and well being of Americans, the cessation rate remains modest (U.S. HHS, 2014). 
Multiple obstacles prevent a successful quit attempt including irritability, anger, 
depressed mood, anxiety and difficulty concentrating. Withdrawal symptom severity is 
not only a direct predictor of relapse (West et al., 1989; al’Absi et al., 2004) but is also 
correlated to the time to relapse (al’Absi et al., 2005). There are currently three FDA 
approved therapies used for targeting the symptoms of withdrawal:  nicotine replacement 
therapy, a nicotinic acetylcholine receptor (nAChR) partial-agonist 
(Varenicline/Chantix®), and an anti-depressant (Bupropion/Zyban®). However, although 
70% of smokers express a desire to quit, current therapies only result in a 15% success 
rate after three months of treatment (Hughes et al., 2004; U.S. HHS, 2014). 
 Chronic nicotine use contributes to multiple alterations in the central nervous 
system, including long-lasting changes in gene expression that may underlie withdrawal 
phenotypes (Martin-Soelch, 2013). One well-characterized protein that alters gene 
expression following chronic nicotine is the transcription factor CREB (cAMP response 
element binding protein). Nicotine regulates CREB signaling in a variety of brain regions 
associated with drug dependence (Hu, 2002; Brunzell et al., 2003) and is necessary for 
nicotine reward (Walters et al., 2005; Brunzell et al., 2009). To date, relevant CREB-
target genes that are regulated during chronic nicotine or withdrawal are not well 
characterized. To identify genes that are altered following chronic nicotine and 24-hour 
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withdrawal, we previously performed chromatin immunoprecipitation (ChIP) analyses 
followed by high-throughput sequencing (ChIP-Seq) and target expression analysis 
(Turner et al., 2014). We focused on the hippocampus, because this brain region is 
strongly associated with nicotine withdrawal symptoms, cue reactivity, and quitting 
success in human neuroimaging studies (Franklin et al., 2007; Wang et al., 2007; 
Froeliger et al., 2010). 
We discovered that within the hippocampus, CREB binding was enriched in a 
number of pathways (Ingenuity Pathway Analysis, see (Turner et al., 2014) for complete 
gene lists). In the category of “cell-to-cell signaling, carbohydrate metabolism, lipid 
metabolism”, we found that CREB binds to the cis-regulatory elements in 12 of 24 
members of the energy-sensing AMPK (AMP-activated protein kinase) pathway as listed 
in the ‘Reactome’ database (Table 2.1). These included several subunits of AMPK itself 
(the genes encoding the β1, β2, γ1 and γ2 subunits) and the upstream regulator of AMPK, 
LKB1 (Liver Kinase B1; also known as Serine/Threonine Kinase 11, STK11). 
Considered the “master regulator” of cellular metabolism, AMPK is a heterotrimeric 
complex composed of one catalytic (α) subunit and two regulatory (β,ϒ) subunits, which 
can be phosphorylated following metabolic stressors including hypoxia, ischemia or 
exercise (Laderoute et al., 2006; Palacios et al., 2009; Li et al., 2010), as well as by 
pharmacological activators including the diabetes drug metformin (Hawley et al., 2002).  
Although the role of AMPK in peripheral tissues is established, few studies have 
focused on its effect within the central nervous system, and none have examined its 
relation to nicotine dependence outside of the hypothalamus. Of importance, recent 
studies illustrate that AMPK signaling is functionally linked to behavior including 
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cognition and negative affect (Dagon et al., 2005; Garabadu and Krishnamurthy, 2014; 
Liu et al., 2014a; Yau et al., 2014; Zhu et al., 2014). As these behaviors are contributing 
symptoms of relapse during nicotine withdrawal, a careful analysis of how alterations in 
AMPK modulate these behaviors following nicotine withdrawal is warranted.  
  Here, we test the hypothesis that modulating AMPK during nicotine withdrawal 
will ameliorate affective and cognitive behaviors observed in mouse models of nicotine 
withdrawal. To test this, we employed a combination of pharmacologic and genetic 
approaches. Specifically, we used the FDA approved drug metformin, the safest first-in-
class therapy for type 2 diabetes (Berkowitz et al., 2014), and an activator of AMPK 
(Zhou et al., 2001). In addition to its anti-diabetic profile, metformin crosses the blood-
brain barrier (Labuzek et al., 2010) and shows promise as a preclinical therapeutic across 
multiple CNS indications (Castellani et al., 2002; Nath et al., 2009; Patil et al., 2014; Liu 
et al., 2014c). Finally, we used a genetic loss-of-function mouse model with a conditional 
deletion of both catalytic α1 and α2 subunits of the AMPK complex to determine if 
alterations in AMPK are causally related to the negative affect behaviors seen following 
nicotine withdrawal.  
 
 
Materials & Methods 
Study Design 
The aim of this study was to examine the impact of AMPK activation on mediating 
anxiety-like behavior and cognition in preclinical models of nicotine withdrawal. To this 
end, mouse studies were conducted where mice received osmotic minipumps containing 
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saline or nicotine (18mg/kg/day) for two weeks. Spontaneous withdrawal from nicotine 
occurred following physical removal of minipumps. All behavioral responses were 
measured between 24-48 hours of withdrawal as the first two days of nicotine withdrawal 
are associated with the highest rate of relapse in humans (Hughes et al., 1992) and with 
peak affective withdrawal symptoms in mice (Damaj et al., 2003). AMPK activators 
(AICAR and metformin) were chronically administered prior to withdrawal from 
nicotine, and behavioral outcomes evaluated using two behavioral paradigms: novelty-
induced hypophagia (NIH) and marble burying (MB).  Fear conditioning was also used as 
a preclinical model of cognitive deficits associated with nicotine withdrawal. 
Experimenters blind to treatment groups measured behavioral endpoints; latency to 
consume (NIH), number of marbles buried (MB) and percent time freezing (fear 
conditioning). Western blotting was used to quantify protein levels of AMPK within 
hippocampal tissue following AICAR or metformin administration. Finally, we used an 
AAV vector to deliver Cre recombinase into Ampkα1loxP/loxP;Ampkα2loxP/loxP mice 
harboring a conditional allele for AMPK to determine if AMPK is necessary for  
mediating the anxiolytic effects of metformin during withdrawal from nicotine.  
 
Animals 
Male 129SvEv;C57Bl/6J F1 hybrid mice 6-8 weeks of age were obtained from Jackson 
Laboratories and used in behavioral paradigms, i.c.v. drug experiment, and molecular 
studies. All AAV-Cre experiments were conducted in previously derived and described 
AMPKαloxP/loxP mice  (AMPKα1loxP/loxP mice previously crossed with AMPKα2loxP/loxP 
mice) (Viollet et al., 2009; Miller et al., 2011) from Dr. Benoit Viollet’s lab (Institut 
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Cochin, INSERM). CREBαΔ mutant mice and wild-type littermates were bred and 
maintained on a 129SvEv and C57BL/6 line for >40 generations. Mice on a C57BL/6 
background were used for all fear conditioning studies due to a strain dependent absence 
of cognitive deficits following nicotine withdrawal in 129SvEv;C57Bl/6J F1 hybrid mice 
(Wilkinson et al., 2013). All mice were maintained on a standard light cycle (lights on 
between 0600 and 1800 h) and had free access to food and water. All experimental 
procedures were approved by the University of Pennsylvania Animal Care and Use 
Committee and were in compliance with the National Institute of Health Guide for the 
Care and Use of Laboratory Animals. 
 
Nicotine: delivery, dose, and withdrawal 
Mice were anesthetized with an isoflurane/oxygen mixture (1-3%), and osmotic 
minipumps (model 1002, Alzet) were placed subcutaneously using aseptic surgery 
techniques. (-)-Nicotine hydrogen tartrate salt (MP Biomedicals) was dissolved in sterile 
0.85% saline and administered in osmotic minipumps at a dose of 18mg/kg/day (dose 
expressed as the freebase weight) for two weeks. Control (saline-treated) mice received 
osmotic minipumps filled with 0.85% saline. Following treatment, minipumps were 
surgically removed from half of the mice receiving saline and from mice treated 
chronically with nicotine to initiate spontaneous withdrawal. 
 
In Vivo Drug Treatments 
Metformin (Spectrum) was dissolved in saline and administered at 250 mg/kg by i.p. 
injection. AICAR (Toronto Research Chemicals) was dissolved in saline and 
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administered at 500 mg/kg by i.p. injection. Vehicle was .85% saline administered by i.p. 
injection. All injections started 7 days prior to withdrawal from nicotine and were given 
once a day between 9-10AM.  
 
Intracerebroventricular administration of Metformin 
Osmotic minipumps (model 2002, Alzet) for i.c.v. delivery were filled with either 0.85% 
saline or metformin (50µg/day), connected to silicone tubing (CT24SR, PlasticsOne), 
push-fit into guide cannula (3300/SP, PlasticsOne), and allowed to equilibrate to 37°C 
overnight. One week after mice were implanted with nicotine minipumps, mice were 
again anesthetized with vaporized isoflurane. The minipump was inserted contralateral to 
the nicotine minipump, and the guide cannula was placed above the right lateral ventricle 
(anteroposterior, -0.8 mm; mediolateral, +1.5 mm) and fixed with dental cement. Six 
days after the surgery nicotine minipumps were removed, and behavioral testing occurred 
at a 24-hour withdrawal timepoint.  
 
Western Blotting 
Protein analysis was performed as previously described (Bang et al., 2012; Chen et al., 
2015). Briefly, tissue was lysed in 50mM Tris (pH 7.4), 150mM NaCl, 1% Triton X-100, 
15% glycerol, phosphatase inhibitor cocktail 2 and 3 (sigma), and protease inhibitor 
cocktail 1 and 2 (Roche). Equal amounts of protein were run on 10% SDS-
polyacrylamide gels. Following SDS-PAGE, and blocking, membranes were incubated 
overnight at 4°C with one of the following antibodies from Cell Signaling Technologies: 
AMPK, phospho-AMPKα, ACC, phospho-ACC or GAPDH. Mouse TrueBlot ULTRA 
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antimouse Ig horseradish peroxidase-conjugated secondary antibody (eBioscience) and 
the SuperSignal West Pico chemiluminescence reagent (Thermo Scientific) were used for 
detection. Quantification of the protein was performed using ImageJ software according 
to their provided protocol. Densities were calculated for each sample and analyzed across 
conditions. 
 
Viruses and microinjections 
The packaging, purification and determination of vector titers for the Adeno-associated 
viruses (AAV9.CMV.PI.eGFp.WPRE.bGH and AAV9.CMV.PI.CRE.rB) were all 
performed by the University of Pennsylvania Vector Core. Injection titers and stereotax 
coordinates were determined as described previously (Gundersen et al., 2013). AAV-Cre 
or AAV-GFP virus were stereotaxically microinjected into the dorsal and ventral 
hippocampus (anterior-posterior-2.1, lateral +/- 1.4, dorsoventral -2.0; and anterior-
posterior -2.9, lateral +/- 3.0, dorsoventral -3.8) at a final titer of 1x1010gc/ul over 20 
minutes using a pressure-injection system (KD Scientific) at 0.1ul/min, 5 minutes per 
coordinate. Behavioral testing began 8 weeks after surgery to allow time for recovery, 
and viral expression.  
 
GFP Immunohistochemistry  
Animals were transcardially perfused with ice-cold PBS followed by ice-cold 4% 
paraformaldehyde (PFA). Brains were removed and fixed overnight in 4% 
paraformaldehyde followed by storage in 30% sucrose, 0.01% sodium azide solution. 
Coronal sections (30µm) were taken using a microtome and stored at 4°C in PBS, 0.01% 
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sodium azide solution until processed for immunohistochemistry. GFP expression was 
enhanced using a chicken-GFP primary antibody (GFP-1020; Aves Laboratories). 
Coronal sections were mounted on slides, washed 3x10 minutes with 1X PBS and 
blocked for 1 hour with 0.1% triton + 3% normal donkey serum in 1X PBS. Following 
blocking, slides were incubated overnight with primary antibody (GFP-1020; Aves 
Laboratories) in blocking solution. The next day, slides were washed 3x10 minutes with 
1X PBS and incubated for two hours with a fluorescent secondary antibody (Alexa Fluor 
647 A31571; Invitrogen). Following incubation with the secondary antibody slides were 
washed, dehydrated and coverslipped with mounting media (Permount). Staining was 
visualized using an epifluorescence microscope (DM5500B, Leica). 
 
Marble Burying  
The marble burying test was conducted as previously described (Turner et al., 2010). 
After 1-hour of acclimation in the room where marble burying testing was performed, the 
mice were placed in a small cage (26x20x14cm) with 5-cm deep bedding, on top of 
which 20 equally distributed marbles lay. The mice were left undisturbed for 15 minutes. 
After 15 minutes, an investigator blind to the treatment group returned the mouse to its 
home cage and counted the number of marbles that were buried in bedding (3/4 or more 
coverage).  
 
Novelty-Induced Hypophagia 
The novelty-induced hypophagia (NIH) test was conducted as previously described (Lee 
et al., 2015) with mice housed in groups of two. Mice were placed in a testing room with 
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dividers separating their home cage and allowed to acclimate for one-hour prior to 
presentation of a palatable food (peanut butter chips; Nestle). Training was repeated over 
10-days with latency to consume the food measured on days 4-10. Following training, 
mice were randomly assigned to a treatment group and implanted with osmotic 
minipumps. Following treatment, latency to consume peanut butter chips over 15-minutes 
was measured in the home cage as a baseline, and then measured again 24-hours later in a 
novel environment. The novel environment consisted of a standard cage with no bedding 
placed within a white box with bright light (~2150 Lux) and a novel smell (1:10) pine 
sol).  
 
Fear Conditioning 
Fear conditioning was conducted as previously described (Portugal et al., 2012; Poole et 
al., 2014). Briefly, minipumps were removed on day 12, and metformin or saline 
treatment started one-week prior to withdrawal. Twenty-four hours following minipump 
removal mice were injected with either metformin or saline and placed into a 
conditioning chamber (Med Associates). Baseline freezing was established as the first 
120 seconds in the chamber. The first auditory stimulus (conditional stimulus (CS); 85dB 
white noise) was presented at 120 seconds and lasted for 30 seconds. During the last two 
seconds of the auditory stimulus a foot-shock (unconditional stimulus (US); 0.57 mA) 
was applied. The second CS-US paring was repeated 120 seconds after the first with 
freezing defined as total lack of movement except for breathing. Testing occurred 24-
hours following training, during 48-hour withdrawal. Mice received an injection of either 
metformin or saline one-hour prior to being returned to the training chamber and assessed 
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for freezing to context for five minutes. Following one-hour, mice were placed into an 
altered context where preCS freezing was measured for 3 minutes followed by 3 minutes 
of measuring freezing to the CS.   
 
Locomotor Activity 
Mice were acclimated for one hour in the room in which testing was performed. Mice 
were tested for 30 minutes in an open-field apparatus (43 x 43 cm2) as previously 
described (Lee et al., 2015) containing 32 photobeams in a 16 x 16 formation (MED 
Associates), and was monitored using Photobeam Activity System Software.  
 
Blood Glucose Monitoring 
Blood was sampled from the tail vein with a Breeze2 Blood Glucose Monitoring System 
(Bayer). Fasting state blood glucose levels were measured using tail vein blood following 
an overnight, 16-hour fast. All blood sampling occurred between the hours of 8-10AM. 
 
Statistical Analysis 
All statistical analysis was conducted using GraphPad Prism 5.0 software package 
(GraphPad Software), and all data are presented as mean ± standard error of mean. For 
comparisons between two groups (e.g., western blot quantification), a Student’s t-test was 
used. For comparisons among multiple groups at one time point (e.g., marble burying, 
fear conditioning), a one-way ANOVA was used. Finally, comparisons between multiple 
groups at different time points (e.g., novelty induced hypophagia), a repeated measures 
two-way analysis of variance (ANOVA) was used to determine significant differences 
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with time (Home day, Novel day) representing the within, repeated-measures 
independent factor, and drug treatment the dependent variable. The threshold for 
statistical significance was set as P < .05, and Bonferonni multiple comparison test was 
used for all post hoc analysis.  
 
 
Results 
pAMPK levels are altered during chronic nicotine and 24-hour withdrawal. To 
evaluate the effects of chronic nicotine and 24-hour withdrawal on the AMPK pathway, 
we performed a protein analysis within the hippocampus following saline, chronic 
nicotine, or 24-hour withdrawal (Fig. 2.1). Results showed a significant increase in the 
ratios of pAMPK to AMPK (one-way ANOVA:  P < 0.05; Fig. 2.1A) and of pACC to 
ACC (phosphorylated Acetyl-CoA carboxylase), a downstream target of AMPK, 
following two weeks of chronic nicotine treatment (one-way ANOVA: P < 0.05; Fig. 
2.1B). In contrast, following 24-hours of withdrawal from nicotine, the ratios of 
pAMPK:AMPK and pACC:ACC decreased significantly (P < 0.05 and P < 0.001 
respectively). Furthermore, the alterations in AMPK following chronic nicotine and 24-
hour withdrawal were absent in mice with targeted deletion of CREB (CREBαΔ mice 
(Hummler et al., 1994; Blendy et al., 1996)), (Fig. 2.1C), indicating that the effects of 
nicotine and withdrawal on AMPK activation are CREB dependent. 
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Improvement in anxiety-like behavior with systemically administered AMPK activators. 
To determine if direct AMPK activation would alter anxiety-like behavior following 
withdrawal from nicotine we used a non-therapeutic agent, AICAR (5-aminoimidazole-4-
carboxamide1-β-D-ribofuranoside) to activate AMPK. AICAR is an adenosine analog 
and a direct allosteric activator of AMPK (Corton et al., 1995). First, we determined if we 
could activate AMPK in the hippocampus following one week of intraperitoneal (i.p.) 
AICAR injections. Seven days of AICAR injections significantly increased the ratio of 
pAMPK to AMPK in the hippocampus (t-test:  P < 0.05; Fig. 2.2A). 
To determine if AMPK activation would alter the anxiety-like behavior observed 
in mice following withdrawal from nicotine, AICAR was administered for one week 
prior to inducing withdrawal. This week of treatment, or “drug run-up”, prior to 
withdrawal models the administration of other nicotine cessation drugs such as 
varenicline (Perkins et al., 2010; Ashare and McKee, 2012). We employed two 
previously validated behavioral paradigms to evaluate anxiety-like behavior in rodents: 
novelty-induced hypophagia (NIH) and marble burying (MB). A reduction in anxiety-like 
behavior was measured by a reduction in latency to feed, and a reduction in the number 
of marbles buried in the NIH and MB tests respectively. In the NIH test (Fig. 2.2B), there 
was a significant main effect of day (F1,31 = 75.47, P = <0.0001), treatment (F3,31 = 3.080, 
P = 0.041) and a day by treatment interaction (F3,31 = 2.986, P = 0.046). Multiple 
comparison tests showed that chronic nicotine treatment significantly reduced anxiety-
like behavior as measured by a decreased latency to eat in a novel environment as 
compared to saline-treated mice (P < 0.05). Furthermore, one-week of AICAR treatment 
prior to and during nicotine withdrawal significantly decreased anxiety-like behavior 
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compared to mice that did not receive AICAR prior to withdrawal (P < 0.05). One week 
of AICAR treatment also significantly reduced latency to feed when compared to the 
saline-treated mice (P < 0.01). 
         In addition, we found that one week of AICAR injections reduced anxiety-like 
behavior during withdrawal in the MB paradigm. A one-way ANOVA identified a 
significant effect of treatment (F3,26 = 7.115, P = 0.001; Fig. 2.2C). Multiple comparison 
analysis showed that prior treatment with AICAR attenuated anxiety-like behavior 
compared to mice that did not receive AICAR prior to 48-hour withdrawal from nicotine 
(P < 0.01). A significant reduction in anxiety was also observed following 48-hour 
withdrawal on AICAR compared to saline-treated control mice (P < 0.01). AICAR 
administration had no effect on body weight or peanut butter chip consumption in the 
home cage (fig. S2.1 A,B), indicating that these factors cannot explain these behavioral 
effects.  
       To close the gap on translating these findings to humans we used the FDA 
approved diabetes medication, metformin, and evaluated its impact on nicotine 
withdrawal behaviors in mice. Metformin has multiple cellular targets including 
activation of AMPK (Owen et al., 2000; Zhou et al., 2001; Hawley et al., 2002; Foretz et 
al., 2010; Miller et al., 2013). Following one-week of systemic metformin treatment the 
ratios of pAMPK to AMPK (t-test:  P < 0.001; Fig. 2.3A,B) and of pACC to ACC (t-test:  
P < 0.01; Fig. 2.3A,C) significantly increased during 24-hour withdrawal as compared to 
mice that received saline prior to withdrawal, confirming a metformin effect on the 
AMPK pathway in the brain. In addition to increasing pAMPK and pACC levels, 
systemic metformin rescued withdrawal-induced anxiety-like behavior in mice. In the 
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NIH test (Fig. 2.3D) there was a significant main effect of day (F1,52 = 105.2, P = 
<0.0001), treatment (F3,52 = 3.053 P = 0.036 ), and a day by treatment interaction (F3,52 = 
2.978, P = 0.039). Multiple comparison tests showed 24-hour withdrawal significantly 
increased anxiety-like behavior as measured by an increased latency to eat in a novel 
environment as compared to chronic nicotine-treated mice (P < 0.05). Following one 
week of metformin treatment, anxiety-like behavior was significantly reduced during 24-
hour withdrawal compared to mice that received saline treatment prior to withdrawal (P < 
0.01). We confirmed this anxiety-like phenotype using the marble burying paradigm, 
observing a significant effect of treatment (F3,41 = 4.871, P = 0.005; Fig. 2.3E). Multiple 
comparison analysis showed that compared to chronic nicotine treatment, nicotine 
withdrawal increased anxiety-like behavior as measured by an increase in the number of 
marbles buried (P < 0.05). In contrast, prior treatment with metformin resulted in a 
reduction of marbles buried during 24-hour withdrawal compared to mice that received 
only saline prior to and during 24-hour withdrawal (P < 0.05). Metformin has been 
associated with weight loss and decreased food consumption in type 2 diabetics (Lee and 
Morley, 1998). However, no significant differences were found in palatable food 
consumption in the home cage, total locomotive activity, or body weight during chronic 
metformin administration (fig. S2.2 A-C). Further, we did not find any alterations in 
either fed or fasted glucose levels, indicating that altered blood glucose levels did not 
contribute to behavioral differences between groups (table S2.1).  
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ICV delivery of metformin reduces anxiety following nicotine withdrawal. Metformin is 
known to have multiple peripheral targets, including the liver and skeletal muscle, and 
changes in pAMPK levels in these organs might indirectly contribute to behaviors 
observed following withdrawal from nicotine. Therefore, we determined the specificity of 
metformin in the brain to elicit anxiolytic behaviors following nicotine withdrawal. We 
implanted mice with osmotic minipumps connected to intracerebroventricular (i.c.v.) 
guide cannulas to deliver either metformin (50µg/day) or saline for one week prior to 
withdrawal. This 50µg/day dose of i.c.v. metformin was chosen because it does not alter 
peripheral glucose metabolism (Portela et al., 2015) and does not induce any 
neuropathological changes including necrosis and hippocampal lesions (Petersen et al., 
2001). Seven days of i.c.v. metformin prior to withdrawal increased the ratio of pAMPK 
to AMPK in the hippocampus during 24-hour withdrawal compared to mice that received 
i.c.v. saline one week prior to withdrawal (t-test:  P < 0.05; Fig. 2.4A), and had no effect 
in the periphery as shown by analysis of the hepatic pAMPK to AMPK ratio (t-test: P = 
0.61; Fig. 2.4B). There was a significant main effect of day (F1,20 = 39.12, P = <0.0001), 
treatment (F2,20 = 4.924 P = 0.01) and a day by treatment interaction (F2,20 = 5.624, P = 
0.01) in the NIH test (Fig. 2.4C). A Multiple comparison test showed that 24-hour 
withdrawal (WD) + i.c.v. saline significantly increased anxiety-like behavior as 
compared to chronic nicotine-treated mice receiving i.c.v. saline (Fig. 2.4C, P < 0.05). 
Importantly, one week of i.c.v metformin treatment significantly reduced anxiety-like 
behavior during 24-hour withdrawal compared to mice that received one week of i.c.v 
saline prior to 24-hour withdrawal (P < 0.001). 
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Deletion of hippocampal AMPKα subunit abolishes anxiolytic effects of metformin. 
Metformin has been shown to activate a variety of cellular targets including activation of 
AMPK (Owen et al., 2000; Zhou et al., 2001; Hawley et al., 2002; Foretz et al., 2010; 
Miller et al., 2013). In order to confirm that AMPK is the target of metformin-mediated 
reduction of anxiety-like behavior following nicotine withdrawal, we utilized 
Ampkα1loxP/loxP;Ampkα2loxP/loxP mice harboring a conditional allele for AMPK 
(AMPKαloxP/loxP). An Adeno-associated virus (AAV) encoding cre recombinase (AAV-
Cre) was microinjected directly into the dorsal and ventral hippocampus of 
AMPKαloxP/loxP mice generating site-specific deletion of AMPKα (Fig. 2.5A). To assess 
the anatomical and temporal expression of AAV, AAV-GFP (green fluorescence protein) 
was injected into the hippocampus of AMPKαloxP/loxP mice and presence of the virus 
confirmed eight weeks later through GFP immunohistochemistry (fig. S2.3A). Western 
blot analysis confirmed that total levels of AMPKα were decreased in the hippocampus 
8-weeks following AAV-Cre injection in AMPKαloxP/loxP mice, but remained unchanged 
in other brain regions such as the cortex (Fig. 2.5B). Further, levels of pACC, were also 
reduced in the hippocampus demonstrating a functional reduction in the pathway (Fig. 
2.5B). Injection of the control virus (AAV-GFP) did not alter AMPK protein expression 
at the injection site (hippocampus) or in the cortex as expected.  
 To assess anxiety-like behavior, mice were trained in the NIH paradigm 4-weeks 
following intrahippocampal injection of either AAV-Cre or AAV-GFP, and testing 
occurred 8-weeks post viral injection to ensure full AMPK ablation (Fig. 2.5C). On the 
novel test day (Fig. 2.5D), there was a significant main effect of day (F1,20 = 75.87, P = 
<0.0001), virus (F1,20 = 12.56, P = 0.002 ) and a day by virus interaction (F1,20 = 10.15, P 
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= 0.004). Bonferroni post hoc test confirmed that metformin does not have anxiolytic 
properties in mice lacking hippocampal AMPKα, as evidenced by the increased latency 
to consume a palatable food in mice injected stereotactically with AAV-Cre compared to 
mice injected with AAV-GFP (P = 0.001).   
 
Metformin improved deficits in fear conditioning following nicotine withdrawal. In 
order to determine if chronic metformin could affect other hippocampal-dependent 
behaviors normally affected by nicotine withdrawal, we utilized the fear conditioning 
paradigm (See Fig. 2.6A for experimental schematic). Withdrawal deficits in contextual 
fear conditioning are hippocampal-dependent and highly reproducible, while cued-fear 
conditioning remains unaffected by nicotine withdrawal in mouse models (Davis and 
Gould, 2007; Portugal and Gould, 2007; Kenney and Gould, 2008; Poole et al., 2014; 
Yildirim et al., 2015). Metformin was given one week prior to and during training and 
testing of contextual and cued fear conditioning. All fear conditioning training occurred 
24-hours following withdrawal from nicotine, followed by testing 24-hours later. A one-
way ANOVA identified a significant effect of treatment on contextual fear conditioning 
(F2,23 = 3.867, P = 0.035; Fig. 2.6B), but not during the baseline test or cued fear 
conditioning. Withdrawal from nicotine-induced contextual learning deficits as measured 
by a significant reduction in time freezing compared to saline-treated mice (P < 0.05). 
However, mice that were withdrawn from nicotine and had received daily metformin 
injections for one week prior to withdrawal showed no significant deficits in contextual 
fear conditioning.  
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Discussion 
Multiple preclinical and clinical studies have explored the influence of targeting 
nicotinic acetylcholine receptors (nAChRs) for smoking cessation therapies. However, 
the limited success and adverse side effects of these aids call for investigation beyond 
targeting nAChRs to abrogate nicotine withdrawal symptoms such as negative affect and 
cognitive deficits. Here, we employed pharmacological, behavioral and genetic 
approaches to identify AMPK activation as a potential novel therapeutic approach for 
nicotine cessation therapy.  
Withdrawal from nicotine produces physiological, affective and cognitive effects 
(Hughes and Hatsukami, 1986; Hughes et al., 1991). The negative affect experienced 
during withdrawal is directly associated with early smoking relapse, with successful 
quitters exhibiting greater positive affect as compared to those that relapse (al’Absi et al., 
2004). Smokers also report that one of their top concerns when considering the 
consequences of abstinence is the loss of nicotine as a tool to cope with negative affect 
(Hendricks et al., 2009).  
To mechanistically examine the anxiogenic effect of nicotine withdrawal in 
preclinical models, we used behavioral paradigms that reliably demonstrate the anxiety 
impairments observed in humans following withdrawal. The novelty-induced hypophagia 
(NIH) test and marble burying test (MB) are two validated methods to evaluate anxiety-
like behavior in rodents. Chronic nicotine exposure reduces anxiety-like behavior as 
measured by a decreased latency to eat a palatable food in a novel environment in the 
NIH test. In contrast, latency is significantly increased following nicotine withdrawal 
(Turner et al., 2014; Yohn et al., 2014; Lee et al., 2015). Similarly, chronic nicotine 
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decreases anxiety-like behavior as measured by a reduction in the number of marbles 
buried while withdrawal increases the number of marbles buried in the MB test (Turner et 
al., 2011; Lee et al., 2015).  
Our findings demonstrate that chronic nicotine activates the AMPK pathway 
(pAMPK, pACC), but this activation is diminished following 24-hour withdrawal. 
AMPK was identified by a whole genome-wide screen for CREB target genes, and, 
importantly, the alterations in the AMPK pathway seen following chronic nicotine and 
24-hour withdrawal were absent in CREB deficient mice, highlighting the validity of 
cistrome analysis for target identification. We hypothesized that by maintaining pAMPK 
levels during nicotine withdrawal, we would mitigate the adverse effects of withdrawal. 
We used the non-therapeutic AMP mimetic AICAR to examine the behavioral effect of 
pharmacologically maintained pAMPK expression levels during nicotine withdrawal. We 
found that one-week of pretreatment with AICAR, at a dose previously described to 
pharmacologically activate AMPK and to alter gene expression within the hippocampus 
(Kobilo et al., 2014), maintained pAMPK expression in the hippocampus and decreased 
anxiety-like behavior following nicotine withdrawal as measured by the NIH and MB 
tests.  
In order to facilitate translation of these findings to the clinic, we examined the 
effect of a FDA approved therapeutic known to activate AMPK, metformin. Metformin is 
an oral pharmacotherapy for type 2 diabetes with over 20 years of clinical safety and 
efficacy data (Bolen et al., 2007). Metformin can readily cross the blood brain barrier 
(Labuzek et al., 2010); however, no previous studies have examined its effects on 
nicotine withdrawal. During 24-hour withdrawal, metformin-treated mice maintained 
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heightened levels of pAMPK in the hippocampus and exhibited decreased anxiety-like 
behavior in the NIH and MB behavioral paradigms compared to saline-treated mice 
during 24-hour withdrawal. In order to determine if the anxiolytic effects of metformin 
are mediated by its action on the peripheral or central nervous system, mice were infused 
with i.c.v metformin one week prior to withdrawal. Mice infused with i.c.v. metformin 
showed an increase in pAMPK in the hippocampus but not in the liver, and a correlative 
reduction in anxiety-like behavior as measured by the NIH test. This further confirmed 
that metformin’s actions within the CNS contribute to its anxiolytic effects during 
withdrawal from nicotine. 
A complementary method to interrogate function involves genetic manipulation, 
such as conditional gene deletion. Conditional deletion of AMPK in peripheral tissues 
has been critical in delineating its function (for review see (Viollet et al., 2009)). 
However, the role of AMPK in mediating the behavioral effects of metformin during 
nicotine withdrawal is not known. Studies in rodents have shown that lesions to the 
hippocampus impact anxiety-like behaviors, including hyponeophagia behavior produced 
in the NIH test (Bannerman et al., 1999; Deacon et al., 2002; Bannerman et al., 2003; 
2004a). Therefore, it is critical to parse out the contribution of hippocampal AMPK in 
mediating the anxiolytic effects of metformin. The catalytic subunit of AMPK exists as 
two isoforms (AMPKα1 and AMPKα2), and although the AMPKα2 isoform is 
predominately expressed in cortical and hippocampal neurons (Turnley et al., 1999), both 
isoforms are expressed in the brain and have redundant functions (Williams et al., 2011; 
Ramamurthy et al., 2014). Therefore, we delivered an AAV vector containing Cre 
recombinase (AAV-Cre) into the hippocampus of AMPKα1loxP/loxP;AMPKα2loxP/loxP 
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(AMPKαloxP/loxP) mice, thus ensuring complete loss of AMPK function. The anxiolytic 
effects of metformin were absent in AMPKαloxP/loxP mice that received AAV-Cre, while 
the anxiolytic effect of metformin remained in control mice. These findings illustrate that 
the AMPKα subunit in the hippocampus is essential in mediating the anxiolytic effects of 
metformin during withdrawal from nicotine in the NIH test. These findings were not 
confounded by changes in locomotion, body weight, or glucose levels, which is 
consistent with other studies that had shown that metformin does not alter fed or fasted 
glucose levels in normoglycemic rodents (Jiang et al., 2014; Sarkaki et al., 2015).  
In addition to negative affect, cognitive deficits in working memory and attention 
following nicotine withdrawal have been well-modeled in humans (Parrott and Roberts, 
1991; Parrott et al., 1996; Hendricks et al., 2006) and rodents (Kenney et al., 2011), and 
can predict smoking relapse following abstinence (Patterson et al., 2010). Further, 
learning and memory tasks that depend upon hippocampal function are also particularly 
sensitive to the detrimental effects of nicotine withdrawal (Davis and Gould, 2007; 
Portugal and Gould, 2007; Kenney and Gould, 2008; Yildirim et al., 2015). In rodents, 
withdrawal from nicotine impairs hippocampal-dependent learning (contextual fear 
conditioning), while having no influence on hippocampal–independent learning (cued 
fear conditioning) (Davis et al., 2005). The contextual fear conditioning deficits observed 
following nicotine withdrawal can be ameliorated following administration of nAChR 
ligands (Raybuck et al., 2008; Yildirim et al., 2015), nAChR substrate modulators (Poole 
et al., 2014), as well as drugs with no direct effect on acetylcholine receptors (Davis and 
Gould, 2007). One week of metformin treatment prior to withdrawal reversed the 
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withdrawal-induced deficits observed during 24-hour withdrawal in contextual fear 
conditioning, without any effect on cued fear conditioning.  
The anxiolytic and cognitive enhancement observed following metformin 
treatment during nicotine withdrawal corroborates other studies that reported a role of 
AMPK signaling in modifying cognition and anxiety in both rodent models and humans. 
AMPK activation in mice results in greater exploratory behavior and decreased anxiety-
like response in a number of behavioral paradigms, including the open field test and 
novelty-suppressed feeding (Garabadu and Krishnamurthy, 2014; Liu et al., 2014b; Yau 
et al., 2014). In contrast, down-regulation of pAMPK is functionally linked to the 
increased anxiety behaviors associated with unpredictable chronic mild stress in mice 
(Zhu et al., 2014). While the role of AMPK in cognition is still unclear, AMPK is 
important for neuronal structure (Ramamurthy et al., 2014), particularly in regulating 
axon growth during metabolic stress (Williams et al., 2011) and during synaptic 
remodeling in older animals (Samuel et al., 2014). Further, AMPK activation by 
environmental stimuli such as diet restriction enhances hippocampal neurogenesis and 
improves performance of mice in the eight-arm maze test of cognition (Dagon et al., 
2005). In humans, AMPK activation following metformin improves cognitive 
performance in type 2 diabetics as measured by increased performance on verbal 
memory, attention and concentration tests, as well as delayed memory tasks (Guo et al., 
2014). Taken together, it is feasible that cognitive deficits seen during nicotine 
withdrawal may improve with metformin treatment.  
While these preclinical results are promising, there are inherent limitations to this 
study. We confirmed that metformin abrogates nicotine withdrawal-induced anxiety-like 
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behaviors through the AMPKα subunit in the hippocampus and can reverse withdrawal-
induced deficits in contextual fear conditioning; however, the exact manner in which this 
occurs remains unknown. As AMPK acts as the master regulator of energy metabolism, it 
is tempting to hypothesize that a dysregulation of neuronal energy homeostasis during 
nicotine withdrawal is contributing to reduced pAMPK levels, resulting in the negative 
affect and cognitive deficits of withdrawal from nicotine. In support of this notion, recent 
reports linked dysfunction of energy metabolism to multiple neurodegenerative, and 
psychosomatic diseases, including Alzheimer’s disease (la Monte and Tong, 2014), 
depression (Gardner, 2003), and biopolar disease (Stork and Renshaw, 2005). Moretti 
and colleagues even suggested that affective disorders are actually “potential energy 
deficiency syndromes,” as energy metabolism modulation can affect neuronal activity 
(Moretti et al., 2003).  
In addition to the role of energy balance in affective disorders, improvement in 
cognitive dysfunction can be functionally linked to improving energy balance, 
specifically mitochondrial function (Pintana et al., 2012). Only one study has examined 
the effects of AMPK on negative energy balance, which focused on hypothalamic AMPK 
following nicotine withdrawal (de Morentin et al., 2012). In the hypothalamus, AMPK is 
activated by orexigenic hormones and suppressed by anorexigenic hormones, 
corresponding to changes in food intake and energy expenditure (Landree et al., 2004; 
Minokoshi et al., 2004). However, it is likely that AMPK serves a very different function 
in the hippocampus than it does in the hypothalamus. Overall, the link between AMPK, 
energy homeostasis, and nicotine withdrawal remains unexamined in the hippocampus 
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and could be related to the mechanisms underlying metformin’s improvement of nicotine 
withdrawal symptoms. 
Based on our findings illustrating the preclinical efficacy of metformin in 
alleviating anxiety-like behavior and cognitive deficits following nicotine withdrawal, we 
propose that AMPK activation in the brain via metformin can be repurposed as a novel 
pharmacotherapy for nicotine cessation. Its efficacy in alleviating withdrawal symptoms 
in addition to its well-established safety profile should encourage investigators to 
translate these studies into future clinical trials for higher continuous abstinence rates in 
smokers.   
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Figure 2.1 Activation of the AMPK pathway following chronic nicotine treatment is 
reduced during 24-hour withdrawal in a CREB-dependent manner. A,B, Western 
blot analyses of AMPK, phospho-AMPK (pAMPK), ACC and phospho-ACC (pACC) in 
mouse hippocampal tissue. The ratio of pAMPK to AMPK protein (A) and pACC to 
ACC protein (B) increased following chronic nicotine (18mg/kg/day) and decreased 
following 24-hour withdrawal from nicotine. C, In CREB deficient mice we observed no 
change in the proportion of pAMPK to AMPK during chronic nicotine or 24-hour 
withdrawal. For each condition, 3 representative data are displayed and * denotes P < 
0.05, *** P < 0.001. 
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Figure 2.2 Chronic AICAR increases pAMPK in the hippocampus and reduces 
anxiety-like behavior during 24-hour withdrawal. A, The ratio of pAMPK to AMPK 
protein levels is increased in the hippocampus following i.p. AICAR (500mg/kg/day) 
administration for one week. For each condition, 3 representative data are displayed and 
quantification (n=4) confirmed the increase in hippocampal pAMPK following treatment 
with AICAR (*P < 0.05). B,C, Mice were implanted with saline or nicotine minipumps. 
After 2-weeks, mice in the withdrawal group had their nicotine minipumps removed to 
initiate withdrawal (WD). Novelty-induced hypophagia (NIH) was tested 24-hours later 
and marble burying (MB) was tested 48-hours later. B, Chronic nicotine reduces the 
latency to approach a palatable food in a novel environment, which is reversed by 
nicotine withdrawal. Importantly, one-week treatment of i.p. AICAR prior to nicotine 
withdrawal prevented the increase in latency to feed observed in saline-treated mice 
undergoing 24-hour withdrawal. Bars represent mean latency ± SEM (n=7-13),* P <0.05, 
** P < 0.01. C, One-week of i.p. AICAR treatment prior to withdrawal reduced the 
amount of marbles buried compared to saline-treated mice and 24-hour withdrawal mice 
that did not receive AICAR. Data represents the mean number of marbles buried over 15 
minutes ± SEM (n = 7-8), ** P < 0.01. 
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Figure 2.3 Systemically administered metformin increases pAMPK in the 
hippocampus and reduces anxiety-like behavior during nicotine withdrawal in the 
novelty-induced hypophagia (NIH) and marble-burying (MB) test. A-C, Western blot 
analysis of hippocampal AMPK, pAMPK, ACC and pACC levels following 24-hour 
nicotine withdrawal in the presence and absence of i.p. metformin. One-week of 
metformin treatment is sufficient to increase both pAMPK:AMPK and pACC:ACC ratios 
in the hippocampus during 24-hour withdrawal. Quantification of western blots (n=6-7), 
** denotes P < 0.01, *** denotes P < 0.001. Mice were implanted with either saline or 
nicotine minipumps. Following 2-weeks of treatment, nicotine minipumps were removed 
in the withdrawal (WD) treatment groups and NIH testing (D) and MB testing (E) 
occurred 24-hours later. D, Mice chronically treated with nicotine exhibited a reduced 
latency to approach a palatable food in a novel environment compared to 24-hour 
withdrawal mice. Mice treated with metformin for one week prior to nicotine withdrawal 
showed a reduced latency to feed during 24-hour withdrawal compared with mice that 
received only saline prior to 24-hour withdrawal. Bars represent mean latency ± SEM (n 
= 13-15), * P < 0.05, ** P < 0.01. E, Withdrawal increased the number of marbles buried 
compared to mice chronically treated with nicotine. Chronic metformin treatment prior 
and during 24-hour withdrawal reduced the amount of marbles buried compared to mice 
that only received saline during withdrawal. Data represents the mean number of marbles 
buried over 15 minutes ± SEM (n = 7-16), * P < 0.05. 
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Figure 2.4 Intracerebroventricular (i.c.v.) metformin maintains elevated pAMPK 
levels and reduces anxiety-like behavior in the NIH during 24-hour withdrawal. A, 
Representative western blot images and quantified data demonstrate increased 
hippocampal pAMPK:AMPK ratio following one-week of i.c.v. administration of 
metformin compared to mice administered i.c.v. saline during withdrawal (n=4 per 
condition), * denotes P < 0.05. B, Liver; an increase in pAMPK was not observed in the 
periphery as measured by no change in the ratio of pAMPK to AMPK (n=5 per 
condition). C, F1 hybrid mice were implanted with nicotine minipumps. One-week later, 
mice were implanted with a second minipump (filled with either saline or metformin) that 
was attached to an i.c.v. guide cannula. One week after this procedure, nicotine 
minipumps were removed to initiate withdrawal (WD). Twenty-four hours later, all mice 
were tested in the NIH paradigm. Mice treated with chronic nicotine + i.c.v. saline 
exhibited a reduced latency to approach a palatable food in a novel environment 
compared to 24-hour withdrawal + i.c.v. saline-treated mice. Mice administered i.c.v. 
metformin one week prior to nicotine withdrawal showed a reduced latency to feed 
during 24-hour withdrawal compared with mice administered saline i.c.v. prior to 24-
hour withdrawal. Bars represent mean latency ± SEM (n = 7-8), * P < 0.05, *** P < 
0.001.  
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Figure 2.5 Efficacy of metformin in alleviating anxiety-like behavior is dependent on 
AMPKα within the hippocampus. A, Coronal sections of the dorsal and ventral 
hippocampus, with red circles illustrating viral injection sites (adapted from Franklin and 
Paxinos (Franklin and Paxinos, 1997)). B, Western blot analysis of AMPKα and pACC in 
the hippocampus of AMPKαloxP/loxP mice 8-weeks following AAV-Cre or AAV-GFP 
injections. AAV-Cre, but not AAV-GFP reduced total AMPKα levels, and pACC levels 
in the hippocampus but not in a region peripheral to the injection site (cortex). C, 
Overview of general experimental paradigm for NIH. AMPKαloxP/loxP mice, at two 
months of age were injected sterotactically with either AAV-Cre or AAV-GFP and 
allowed to recover for four weeks for full AMPK ablation. Mice were then trained for the 
NIH test, treated with chronic nicotine, and NIH behavior examined 24-hours following 
withdrawal from nicotine. D, Chronic metformin treatment does not reduce anxiety in 
AMPKαloxP/loxP mice injected with AAV-Cre, evidenced by an increased latency to 
approach a palatable food in a novel environment during 24-hour withdrawal compared 
to metformin-treated AMPKαloxP/loxP mice injected with AAV-GFP. Bars represent mean 
latency ± SEM (n = 6-7), *** P < 0.001.  
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Figure 2.6 Metformin ameliorates deficits in contextual fear conditioning observed 
in C57BL/6 mice withdrawn from nicotine. A, Experimental schematic for contextual 
and cued fear conditioning during nicotine withdrawal. Training in conditional chambers 
occurred at 24-hour withdrawal and consisted of two CS-US pairings, each 30 seconds 
long over a 5-minute time period. For the context test, mice were placed back into the 
conditioning chambers 24-hours following training (48-hour withdrawal) for five 
minutes. The cued test occurred one hour later and consisted of 3 minutes pre-CS, 3 
minutes CS. B, A deficit in contextual but not cued fear conditioning was observed in 
mice withdrawn from nicotine, but not in mice that had received metformin treatment for 
one week prior to withdrawal, and during both training and testing. Bars represent mean 
percent freezing ± SEM (n = 8-9), * P < 0.05.   
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   Table 2.1 Members of the AMPK pathway bound  
   by CREB in the hippocampus 
 
 
 
 
!
Gene$Symbol! Gene$Name!Acacb! Acetyl*CoA!carboxylase!beta!Acsl1! Acyl*CoA!synthetase!Cab39L! Calcium!binding!protein!39!Ppm1a! Protein!phosphatase!1A!Prkab1! AMPK,!beta!1!subunit!Prkab2! AMPK,!beta!2!subunit!Prkag1! AMPK,!gamma!1!subunit!Prkag2! AMPK,!gamma!2!subunit!Rheb! Ras!homolog!enriched!in!brain!Rptor! Raptor,!regulator!of!MTO!Stk11! Serine/Threonine!Kinase!11!Tsc1! Tuberous!sclerosis!1!
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figure S2.1 One week of chronic AICAR treatment does not alter body weight or 
palatable food consumption. A, Body weight was not affected by one-week of AICAR 
(500mg/kg/day) treatment. Values are plotted as mean ± SEM (n= 7-8). B, Peanut butter 
chips were placed in the home cage during NIH home day following 6 days of AICAR 
treatment. No change in consumption of the palatable food (peanut butter chips) was 
observed. Bars represent the average grams of peanut butter chips consumed during 15 
minutes in the home cage ± SEM (n = 8-16). 
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figure S2.2 One week of chronic metformin treatment does not alter palatable food 
consumption, total locomotive activity or body weight. A, Peanut butter chip 
consumption in the home cage was measured 6 days following metformin treatment. No 
change in consumption of the palatable food (peanut butter chips) was observed during 
15 minutes in the home cage. Bars represent the average grams of peanut butter chips 
consumed ± SEM (n = 8). B, We found no differences in total locomotive activity 
measured in open field. Bar graphs represent the average total distance moved over 30 
minutes ± SEM (n= 7-8). C, We found no effect of saline or metformin (250mg/kg/day) 
injections on body weight. Values are plotted as mean body weight ± SEM (n= 8-9). 
 
 
 
 
                       figure S2.3 Intrahippocampal injection of AAV-GFP in 
                       mouse hippocampus. A, Bilateral GFP expression throughout 
                       the mouse hippocampus, 8-weeks following stereotaxic 
                       injection of AAV-GFP. 
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figure S2.4 ICV administration of saline and metformin does not alter palatable 
food consumption in the NIH paradigm during the home day test (15 minutes). 
Peanut butter chip consumption in the home cage was measured 6 days following i.c.v. 
saline and i.c.v. metformin administration. Bars represent the average grams of peanut 
butter chips consumed ± SEM (n = 7-8). 
	  
 
Groups	   	  	   Fed	  Glucose	  (mg/dl)	   	  	   	  	  
Fasted	  Glucose	  
(mg/dl)	  ****	  
Saline	  
	  
134.1	  ±	  4.260	  
	   	  
89.22	  ±	  2.465	  
Nicotine	   	  	   132.1	  ±	  3.795	   	  	   	  	   91.0	  ±	  4.639	  
Nicotine	  WD	  
	  
133.3	  ±	  2.226	  
	   	  
88.63	  ±	  3.664	  
Nicotine	  WD	  +	  Metformin	   135.5	  ±	  3.536	   	  	   	  	   95.88	  ±	  5.524	  
 
                table S2.1 Blood glucose concentrations in mice fed ad libitum and 
                following a 16-hour fast. While fasting significantly decreased blood  
                glucose levels for all groups   (**** P < 0.0001), we did not observe  
                any significant effect of drug treatment. Error bars indicate ± SEM,  
                WD represents 24-hour Withdrawal.  
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Abstract 
Introduction: Nicotine withdrawal is characterized by both affective and cognitive 
symptoms. Identifying genetic polymorphisms that could affect the symptoms associated 
with nicotine withdrawal are important in predicting withdrawal sensitivity and 
identifying personalized cessation therapies. In the current study we used a mouse model 
of a non-synonymous single nucleotide polymorphism in the translated region of the 
brain-derived neurotrophic factor (BDNF) gene that substitutes a valine (Val) for a 
methionine (Met) amino acid (Val66Met) to examine the relationship between the 
Val66Met single nucleotide polymorphism and nicotine dependence.  
Methods: This study measured proBDNF and the BDNF prodomain levels following 
nicotine and nicotine withdrawal and examined a mouse model of a common 
polymorphism in this protein (BDNFMet/Met) in three behavioral paradigms: novelty-
induced hypophagia, marble burying, and the open-field test.  
Results: Using the BDNF knock-in mouse containing the BDNF Val66Met 
polymorphism we found: (1) blunted anxiety-like behavior in BDNFMet/Met mice 
following withdrawal in three behavioral paradigms: novelty-induced hypophagia, 
marble burying, and the open-field test; (2) the anxiolytic effects of chronic nicotine are 
absent in BDNFMet/Met mice; and (3) an increase in BDNF prodomain in BDNFMet/Met 
mice following nicotine withdrawal.  
Conclusions: Our study is the first to examine the effect of the BDNF Val66Met 
polymorphism on the affective symptoms of withdrawal from nicotine in mice. In these 
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mice, a single-nucleotide polymorphism in the translated region of the BDNF gene can 
result in a blunted withdrawal, as measured by decreased anxiety-like behavior. The 
significant increase in the BDNF prodomain in BDNFMet/Met
 
mice following nicotine 
cessation suggests a possible role of this ligand in the circuitry remodeling after 
withdrawal.  
 
Introduction 
Smoking is the leading cause of preventable death in developed countries 
(Adhikari et al., 2009). However, despite the numerous health risks less than 10% of quit 
attempts result in continuous abstinence for 1 year (CDC, 2014). Nicotine, the primary 
addictive component of tobacco, acts on brain nicotinic acetylcholine receptors to 
increase neuronal dopamine activity within the mesolimbic reward circuit (Wu, 2010). 
Altered homeostasis of this brain reward system results in complex behaviors such as 
dependence, tolerance, sensitization, and craving (De Biasi and Dani, 2011). These 
behaviors all contribute to the symptoms of withdrawal, which include irritability, 
depressed mood, and anxiety.  
One key molecule acting in the reward system is brain-derived neurotrophic 
factor (BDNF), a secreted factor of the neurotrophin family necessary for the growth 
(Segal et al., 1995), differentiation (Leschik et al., 2013), and survival (Hofer and Barde, 
1988) of neurons. Genetic modulation of BDNF or its receptor, TrkB, alters the 
rewarding effect of drugs of abuse such as cocaine and alcohol (Hall et al., 2003; Hensler 
et al., 2003; Unterwald et al., 2013), linking BDNF to addiction. Smoking also increases 
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plasma BDNF levels in humans (Kim et al., 2007; Bhang et al., 2010) and administered 
nicotine increases BDNF gene expression in critical regions of the mesolimbic reward 
circuit of rodents (Kivinummi et al., 2011).  
Recently, the relationship between smoking and a non-synonymous single 
nucleotide polymorphism (SNP) in the translated region of the BDNF gene was 
investigated. This SNP substitutes a valine (Val) for a methionine (Met) amino acid 
(Val66Met) and is fairly common with 37% of individuals of European ancestry carrying 
the Met allele (Consortium, 2012). The SNP occurs within the prodomain of the BDNF 
gene, a region where the chaperone protein sortilin is known to bind and mediate 
intracellular trafficking in the secretory pathway (Chen et al., 2005). The BDNF 
Val66Met SNP reduces activity-dependent secretion of BDNF (Egan et al., 2003) without 
affecting constitutive secretion or mature levels of the peptide, and leads to alterations in 
the dendritic complexity of hippocampal neurons and total hippocampal volume (Chen et 
al., 2006). This SNP has been associated with anxiety (Chen et al., 2006), hypothalamic-
pituitary-adrenal axis reactivity to stress (Alexander et al., 2010; Colzato et al., 2011), 
depression (Tsai et al., 2010), posttraumatic stress disorder (Zhang et al., 2014), and 
substance abuse (Gratacòs et al., 2007). The importance of the Val66Met SNP and 
nicotine dependence remains unclear as studies report conflicting results on the 
association between the SNP and smoking behavior (Lang et al., 2007; Montag et al., 
2008). However, a recent study looking at the association between the BDNF Val66Met 
SNP and smoking cessation found that the SNP is associated with an increased percent of 
successful quitting (Breetvelt et al., 2012). Furthermore, studies utilizing a knock-in 
mouse containing the BDNF Val66Met variant demonstrate that this SNP can alter 
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affective behavior. Specifically, mice harboring the Met amino acid substitution on both 
chromosomes (BDNFMet/Met) show increased baseline anxiety-like behavior as measured 
in the open field and elevated plus maze (Chen et al., 2006) as compared to wildtype 
control mice harboring a Val amino acid substitution on both chromosomes 
(BDNFVal/Val). A more thorough investigation into the role of the Val66Met SNP on 
behavioral affect following smoking cessation is needed, as symptoms including 
depressed mood and anxiety are contributing factors for relapse (Hughes, 1992; 2007b). 
The current study utilized a knock-in mouse containing the BDNF Val66Met variant to 
examine the role of this SNP in mediating the negative behavioral affect following 
withdrawal from nicotine.  
 
 
 
Materials & Methods  
 
Animals 
 
BDNF Val66Met mice were generated using a knock-in allele with a point mutation (G to 
A at position 196) in the coding region of the mouse BDNF gene as described previously 
(Chen et al., 2006). These mice were bred at the University of Pennsylvania for use in 
these experiments. Mice (23–38g; 2–4 months old) had ad libitum access to food and 
water, and were maintained on a 12 hour/12 hour light/dark cycle (lights on at 07:00 
hours). All experimental procedures were conducted during the light cycle at the 24-hour 
nicotine withdrawal time point. Animals were housed in groups (3–5) except for the 
novelty-induced hypophagia (NIH) paradigm where mice were housed in groups of two. 
Equal numbers of male and female mice were used for all studies. All experimental 
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procedures were approved by the University of Pennsylvania Animal Care and Use 
Committee and were in compliance with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals.  
 
Surgical Procedures and Drugs 
Mice were anesthetized with an isoflurane/oxygen vapor mixture (1%–3%) and placed in 
a stereotaxic frame. Osmotic minipumps (model 2002; Alzet, Cupertino, CA) were 
placed subcutaneously using aseptic surgery techniques. (-)-Nicotine hydrogen tartrate 
salt (Sigma, St. Louis, MO) was dissolved in sterile 0.85% saline and administered in 
osmotic minipumps at a dose of 18mg kg
-1 day
-1 (dose expressed as the freebase weight) 
for 2 weeks. Following chronic nicotine or saline treatment minipumps were surgically 
removed from mice receiving nicotine to initiate withdrawal as well as from ½ of the 
saline-treated mice to control for the effects of surgery.  
 
Behavioral Experiments 
For behavioral testing, independent cohorts were used to evaluate anxiety-like behavior 
in each of the three tests: NIH, marble burying, and open field. All behavioral testing 
occurred at the 24-hour withdrawal time point (Figure 3.1A) and was conducted between 
the hours of 9:00 AM and 2:00 PM. Mice were acclimated to the behavioral testing 
facility 1 hour prior to testing for all studies.  
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Novelty Induced Hypophagia 
The NIH test was conducted as previously described (Turner et al., 2014; Yohn et al., 
2014) with mice housed in groups of two. Mice were placed in a testing room with 
dividers separating their home cage, and allowed to acclimate for 1 hour prior to 
presentation of a palatable food (peanut butter chips; Nestle, Glendale, CA). Training was 
repeated over 14 days with latency to consume the food measured on days 4–14. 
Following training, mice were assigned to a 2-week treatment group and implanted with 
osmotic minipumps (Figure 3.1A). Following treatment, latency to consume food chips 
over 15 minutes was measured in the home cage as a baseline, and then measured again 
24-hours later in a novel environment. The novel environment consisted of a standard 
cage with no bedding placed within a white box with bright light (~2150 Lux) and a 
novel smell (1:10 pine sol).  
 
Marble Burying 
The marble burying task was conducted as previously described (Turner et al., 2011). 
Mice were placed in a small cage (26×20×14cm) with 5-cm deep bedding, on top of 
which 20 equally distributed marbles lay. Following a 1-hour acclimation to the testing 
room mice were placed into the cage with the marbles and left undisturbed for 15 
minutes. After 15 minutes, an investigator blind to the treatment and genotype group 
removed the mouse and counted the number of marbles that were buried in bedding (3/4 
or more coverage).  
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Open Field and Locomoter Activity 
Locomoter activity was measured in a Plexiglas arena (43×43cm2) containing 32 
photobeams in a 16 × 16 formation (MED Associates, St. Albans, Vermont), and was 
monitored using Photobeam Activity System software. The 6×6 square region in the 
middle of the box was defined as the central region. Three parameters were measured in 
5-minute increments over 30 minutes: total distance travelled, entries into center, and 
time spent in central region.  
 
Statistical Analysis 
Statistical analyses were carried out using the GraphPad Prism 5.0 software package 
(GraphPad Software, San Diego, CA), and all data are presented as mean ± standard error 
of mean. Data analysis for training during the NIH was performed using the Log-rank test 
(Mantel–Cox) to identify significant genotype differences in the time to first food 
consumption in the NIH training paradigm (Figure 3.1B). For the NIH test, a repeated 
measures two-way analysis of variance (ANOVA) was used to determine significant 
differences with genotype and treatment as between subject factors and time (Home day, 
Novel day) representing the within, repeated-measures factor (Figure 3.1D). For the 
marble-burying experiment and open field test a two-way ANOVA with genotype and 
treatment as the two factors was used (Figure 3.3 and 3.4). In the open field a cross-over 
interaction was detected, but as our predicted hypothesis was that withdrawal would be 
anxiogenic in BDNFVal/Val mice a one-tailed t-test was used to compare 24-hour 
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withdrawal to saline-treated mice in both genotypes. ANOVA was used to analyze 
genotype and treatment differences in proBDNF and the BDNF prodomain (Figure 3.4). 
The threshold for statistical significance was set as P < .05, and Fishers least significant 
difference test was used for all post-hoc analysis of multiple comparisons when an 
interaction was detected.  
 
Western Blot 
Protein analysis was performed as previously described (Portugal et al., 2012; Anastasia 
et al., 2013). Hippocampi from BDNFVal/Val and BDNFMet/Met mice treated with either 
saline, chronic nicotine (18mg kg
-1 day
-1
) or undergoing 24-hour withdrawal was 
homogenized and lysed in 1% triton X-100 (Sigma), 1% nonidet P-40 (Roche, 
Indianapolis, IN) in Tris-buffered saline pH 7.4 with protease inhibitor cocktail (Sigma). 
Protein concentration was quantified by Bradford (Bio-Rad, Hercules, CA). Equal 
amounts of protein were run on SDS-polyacrylamide gels (SDS- PAGE). After 
transference to PVDF membranes, proteins were fixed to the membrane with 2.5% 
glutaraldehyde in phosphate buffered saline pH 7.4 as described previously (Dieni et al., 
2012; Anastasia et al., 2013). Membranes were blocked with 5% bovine serum albumin, 
then incubated with the prodomain antibody (mAb287, 1:2000, 12–16 hours at 4°C, 
GeneCopoeia, Rockville, MD), (Yang et al., 2009) BDNF antibody (Santa Cruz 
Biotechnology), and actin antibody (Sigma). Membranes were then incubated with anti- 
mouse or anti-rabbit horseradish peroxidase secondary antibody for 1 hour at 20°C–25°C. 
Visualization and quantification of the protein was performed using enhanced 
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chemiluminescence (Amersham-GE, Pittsburg, PA) and ImageJ (1.45, NIH, Bethesda, 
MD). proBDNF and BDNF prodomain densities were normalized to actin for each 
sample.  
 
 
Results 
NIH: Anxiolytic Effect of Nicotine and Anxiogenic Effect of Withdrawal are Blunted 
in BDNFMet/Met Mice. To examine the effect of the BDNF Val66Met polymorphism on 
anxiety-like behavior we used the NIH test. In the NIH test, reduction in feeding in 
response to a novel environment is a well-established measure for anxiety-related 
behaviors (Dulawa and Hen, 2005). When training mice to eat a palatable food we found 
that the BDNFMet/Met mice took a significantly longer time to first approach and eat the 
food when compared with the BDNFVal/Val mice (log-rank test (P < .0001; Figure 3.1B). 
The BDNFVal/Val mice all ate the food within 3 days, while the BDNFMet/Met mice did not 
all eat until day 9 of training. However, total food intake of PB chips was the same across 
genotypes and treatment groups (Figure 3.1C). Latencies to consume increased on novel 
day as indicated by a main effect of day (F(1,64)= 109.6, P < .0001; Figure 3.1D). Two-
way ANOVA also identified a main effect of treatment by genotype (F(5,64)= 3.528, P = 
.007) and an interaction of day by treatment (F(5,64)= 3.976, P = .0033). Fisher’s LSD 
post-hoc identified a significant decreased latency to consume in BDNFVal/Val mice 
treated with nicotine as compared to saline treated mice (P < .01). In contrast, following 
24-hour withdrawal from nicotine, BDNFVal/Val mice displayed a significant increase in 
	  
	  
70	  
latency to consume when compared to chronically treated nicotine mice (P < .0001). The 
anxiogenic effect of withdrawal seen in BDNFVal/Val mice was not seen in BDNFMet/Met 
mice. As shown in Figure 3.1D, there was a significant decrease in latency to consume in 
the BDNFMet/Met mice undergoing 24-hour withdrawal as compared to BDNFVal/Val mice 
undergoing withdrawal (P < .0001). BDNFMet/Met mice also showed a significant decrease 
in latency to consume during 24-hour withdrawal when compared to BDNFMet/Met
 
saline-
treated mice (P < .01). In addition, the anxiolytic effect of chronic nicotine treatment 
observed in the BDNFVal/Val mice was not significant in the BDNFMet/Met mice.  
 
Marble Burying: BDNFMet/Met Mice Exhibit Heightened Anxiety-Like Behavior, Which 
is Attenuated Following 24-Hour Withdrawal From Nicotine. We used the marble 
burying test to further investigate the effect of the BDNF Val66Met polymorphism on 
anxiety-like behavior following 24-hour withdrawal (Figure 3.2). In the BDNF Val66Met 
mice, there was a significant genotype × treatment interaction on the number of marbles 
buried (F(1,46)= 4.164, P = .047). Further post-hoc analysis for multiple comparisons 
revealed that BDNFMet/Met saline-treated mice exhibited greater baseline anxiety-like 
behavior as measured by an increased number of marbles buried compared to BDNFVal/Val 
saline-treated mice (P = .046). Following 24-hour withdrawal there were no differences 
in the number of marbles buried between the BDNFMet/Met and the BDNFVal/Val
 
mice (P = 
.815). However, there was a significant decrease in the number of marbles buried in the 
BDNFMet/Met mice following 24-hour withdrawal as compared to BDNFMet/Met saline-
treated mice (P = .033).  
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Open Field: 24-Hour Withdrawal in BDNFMet/Met Mice Differentially Alters Anxiety-
Like Behavior When Compared to BDNFVal/Val Mice Undergoing 24-Hour Withdrawal. 
The open field test was used to further evaluate spontaneous locomotor activity and 
anxiety-like behavior in BDNFVal/Val and BDNFMet/Met mice following 24-hour 
withdrawal (Figure 3.3A-D). A two-way ANOVA indicated a treatment by genotype 
interaction for time in center (F(1,27)= 4.445, P = .04; Figure 3.3A) and entries into center 
(F(1,27) = 4.680, P = .03; Figure 3.3B) but no main effect of genotype or treatment. During 
24-hour withdrawal BDNFVal/Val
 
mice exhibited decreased time spent in the center (t16= 
1.910, P < .05; Figure 3.3A) while BDNFMet/Met did not show this decrease. To further 
analyze the genotype × treatment effect on novelty induced locomotion in the open field 
the first 5 minutes of the session were analyzed and revealed a genotype by treatment 
interaction (F(1,27)= 4.950, P = .03; Figure 3.3C) with BDNFMet/Met mice showing 
increased time spent in the center for the first 5 minutes following 24-hour withdrawal 
(t10= 1.960, P < .05; Figure 3.3C), with no difference evident in BDNFVal/Val mice. No 
effect of genotype or treatment was observed on total locomotive activity (Figure 3.3D).  
 
BDNF Prodomain is Upregulated Following 24-Hour Withdrawal in the Hippocampus 
of BDNFMet/Met Mice, While proBDNF Remains Unchanged Across Genotypes and 
Treatments. We used western blot analysis to determine if proBDNF (~32kDa) or BDNF 
prodomain (~15.5kDa) levels were dysregulated during chronic nicotine treatment and 
24-hour withdrawal. As shown in Figure 3.4, proBDNF levels are significantly lower in 
hippocampi from BDNFMet/Met compared to BDNFVal/Val mice regardless of treatment 
(one-way ANOVA P = .025; Figure 3.4A). The BDNF prodomain was also decreased in 
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BDNFMet/Met mice in the saline and nicotine-treated groups. However, in BDNFMet/Met 
mice, BDNF prodomain levels were significantly elevated at the 24-hour withdrawal time 
point (one-way ANOVA: P < .0002; Figure 3.4B). No increase in BDNF prodomain 
levels was observed in BDNFVal/Val mice.  
 
Discussion 
In this study we utilized a BDNF Val66Met mouse model to examine the effects 
of this polymorphism on mediating anxiety-like behavior following withdrawal from 
nicotine. Nicotine withdrawal induces an increased anxiety state in both human (Picciotto 
et al., 2002; Dani and Harris, 2005; Pomerleau et al., 2005; Hogle et al., 2010; Piper et 
al., 2011) and animal models (Irvine et al., 2001; Jonkman et al., 2005; Jackson et al., 
2008; Stoker et al., 2008; Jackson et al., 2009). By utilizing three behavioral paradigms 
known to assess anxiety-like behavior, we found that BDNFMet/Met mice have reduced 
anxiety-like behavior following nicotine withdrawal. This is the first finding to our 
knowledge that uses this mouse model of a human genetic variant to examine nicotine 
withdrawal phenotypes and suggests that this model could be used to identify molecular 
markers for withdrawal sensitivity in humans.  
In humans, the negative affect experienced during withdrawal is directly 
associated with early smoking relapse with relapsers exhibiting a greater decrease in 
positive affect as compared to successful quitters (al’Absi et al., 2004). Withdrawal 
symptoms such as anxiety are not only related to the success of quitting but are also 
related to the time to relapse (al’Absi et al., 2005). For this reason, it is important to 
examine anxiety-like behavior at this early withdrawal timepoint in mice.  
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Studies in rodents have shown that lesions to the hippocampus impact anxiety-
like behaviors, including hyponeophagia (Bannerman et al., 2003; 2004b; McHugh et al., 
2004; Kalisch et al., 2006; McHugh et al., 2010). Hippocampal volume can also be 
correlated with anxiety levels in patients with anxiety disorders (Bremner et al., 1995), 
and is associated with successful quit attempts (Froeliger et al., 2010). Of interest, 
irregular activation in the hippocampus has been associated with affect in smokers during 
smoking cue presentation (McClernon et al., 2008). Furthermore, the BDNF Val66Met 
polymorphism is associated with altered hippocampal function and activity (Egan et al., 
2003; Hariri et al., 2003). Thus, alterations of BDNF in the hippocampus together with 
the known behavioral phenotypes observed in the BDNFMet/Met mice suggested that this 
anxiety behavior might be dysregulated following nicotine withdrawal.  
The NIH test is sensitive to both the effects of chronic nicotine and withdrawal 
from nicotine in mice (Turner et al., 2010; 2014; Yohn et al., 2014). In particular, studies 
have shown an anxiolytic effect of chronic nicotine as measured by a decreased latency to 
consume a palatable food in a novel environment when compared to saline-treated mice. 
In contrast, an anxiogenic effect of withdrawal at 24 hours is observed as an increased 
latency to consume a palatable food in a novel environment when compared to nicotine-
treated mice (Turner et al., 2010; 2011; Hussmann et al., 2014; Turner et al., 2014; Yohn 
et al., 2014).  
The increased time observed in the BDNFMet/Met mice to initially approach and eat 
the palatable food during training for the NIH test (Figure 3.1B) might be indicative of 
either increased anxiety-like behavior as the food is a novel object introduced into the 
home cage, or it could be revealing a deficit in training behavior as studies have shown 
	  
	  
74	  
that the BDNFMet/Met mice exhibit impaired spatial and working memory (Wang et al., 
2013). However, no significant differences between genotype or between treatment 
groups by the end of training were observed, suggesting that although acquisition of the 
task was slow, it did not affect the overall performance of these mice on home or novel 
day.  
During 24-hour withdrawal, BDNFMet/Met mice showed a decreased latency to 
consume a palatable food, indicative of a decreased anxiety-like response, when 
compared to wildtype (BDNFVal/Val) mice undergoing 24-hour withdrawal (Figure 3.1). 
This effect was further reflected in the marble-burying and open-field tests (Figure 3.2 
and 3.3). In marble burying there was a significant increase in anxiety-like behavior at 
baseline in the BDNFMet/Met mice as exhibited by increased number of marbles buried, 
compared to BDNFVal/Val mice at baseline (Figure 3.2). An increase in baseline anxiety-
like behavior has previously been reported in BDNFMet/Met mice in elevated plus maze, 
open field, and NIH tests (Chen et al., 2006). The baseline heightened anxiety phenotype 
in the BDNFMet/Met mice was lost following 24-hour withdrawal. In the open field test, 
BDNFMet/Met mice did not show the increased anxiety-like behavior seen in BDNFVal/Val 
mice following 24-hour withdrawal as exhibited by a decreased time spent in the center 
of the open field. BDNFMet/Met mice also exhibited increased exploratory behavior during 
the first 5 minutes of the open field test while undergoing 24-hour withdrawal from 
nicotine in contrast to the BDNFVal/Val mice undergoing withdrawal (Figure 3.3). 
Chronic nicotine treatment also had a different effect dependent on the BDNF 
Val66Met genotype. BDNFVal/Val mice showed the expected decreased latency to 
consume following chronic nicotine, indicative of decreased anxiety-like behavior. In 
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contrast, while there was a trend, chronic nicotine did not significantly attenuate anxiety-
like behavior in the BDNFMet/Met mice as measured by the NIH test (Figure 3.1D). Drugs 
other then nicotine that are known to modulate BDNF, such as fluoxetine, also have 
dampened sensitivity in BDNFMet/Met mice as measured by the novelty-induced 
hypophagia test (Chen et al., 2006). The behavioral responses in the NIH test are not due 
to altered spontaneous locomotion or food consumption on novel day (Figure 3.1C; 
Figure 3.3D).  
No changes in proBDNF were found across treatments, with overall lower levels 
of proBDNF displayed in the hippocampus of BDNFMet/Met mice (Figure 3.4A). These 
results duplicate a previous finding that the Val66Met SNP reduces activity dependent 
secretion of proBDNF (Hashimoto, 2007). ProBDNF is critically involved and abundant 
in early postnantal development (Yang et al., 2009). However, one of the cleaved 
products of proBDNF, the BDNF prodomain, is present and abundant during adulthood 
(Anastasia et al., 2013). A recent study demonstrated that the BDNF prodomain is not 
only abundant in the hippocampus but also secreted in an activity dependent manner 
(Anastasia et al., 2013). Of particular interest, the study showed that the Met66 
prodomain is biologically active, alters neuronal morphology and induces growth cone 
retraction. Similar to previous studies we also detected lower levels of BDNF prodomain 
in the hippocampus of BDNFMet/Met mice compared to BDNFVal/Val mice (Bath et al., 
2012; Anastasia et al., 2013). Of interest, we saw an increase in the BDNF prodomain 
during 24-hour withdrawal in the hippocampus of BDNFMet/Met mice (Figure 3.4B). While 
the functional significance of this upregulation was not studied, it correlates with the 
blunted anxiety behaviors seen in BDNFMet/Met mice during 24-hour nicotine withdrawal. 
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Thus, it is possible that the Met66 prodomain is a novel ligand that may be required for 
circuitry remodeling after nicotine withdrawal. Future studies looking at the role of this 
novel ligand on behavior are of interest.  
It is of great clinical significance to understand how the BDNF Val66Met SNP 
affects the behavior associated with 24-hour nicotine withdrawal. Although multiple 
studies have shown the effect of the BDNF Val66Met variant on anxiety-related 
behaviors, it’s effect on smoking initiation and dependence has elicited mixed clinical 
results (Lang et al., 2007; Montag et al., 2008). Studies focusing on the effect of the SNP 
on withdrawal from nicotine are just emerging. A recent study found a significant 
association of the SNP with smoking cessation where the Met/Met genotype was 
associated with increased cessation rates as compared to the Met/Val genotype in a large 
population-based sample (Breetvelt et al., 2012). Given the role of anxiety and negative 
affect seen in human populations following withdrawal from nicotine it is tempting to 
hypothesize that the increased cessation rates observed in the Met/Met population could 
be due to a decreased prevalence of negative affect following withdrawal, as 
demonstrated in our rodent studies. In conclusion, clinical studies investigating this SNP 
in nicotine withdrawal, and rodent studies continuing to look at the molecular 
underpinnings of the behaviors in these mice following withdrawal are necessary to 
further explain the effect of this SNP on smoking and withdrawal behavior in humans.  
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Figure 3.1 Behavioral effects of the mouse brain-derived neurotrophic factor 
(BDNF) Val66Met variant in the novelty-induced hypophagia (NIH) test. Mice from 
the following groups: BDNFVal/Val; saline (n = 17), nicotine (n = 12), 24-hour withdrawal 
(WD) (n = 13) and BDNFMet/Met; saline (n = 9), nicotine (n = 10), 24-hour WD (n = 9) 
were run in the NIH test. A, Experimental paradigm for nicotine delivery and time frame 
for behavioral testing. Osmotic minipumps were implanted on day 1 after animals were 
randomly assigned to a treatment group and counterbalanced for sex and genotype. All 
behavioral testing occurred on day 14, following 24-hour withdrawal in the withdrawal 
treatment group. Training for the NIH test training occurred day 1 to day 14. B, 
BDNFMet/Met mice take significantly longer to first approach and consume the palatable 
food during training for the NIH paradigm compared to BDNFVal/Val mice. C, No 
difference in food intake is observed on novel day regardless of treatment or genotype. D, 
BDNFVal/Val mice chronically treated with nicotine exhibit a reduced latency to feed on 
novel test day compared with saline controls and 24-hour withdrawal. BDNFMet/Met mice 
exhibit a reduced latency to feed during 24-hour withdrawal compared with BDNFVal/Val 
mice undergoing withdrawal and BDNFMet/Met saline-treated mice. Significant compared 
with BDNFVal/Val 24-hour withdrawal—****P < .0001. Significant compared with 
BDNFVal/Val chronic nicotine—##P < .01. Significant compared with BDNFMet/Met vehicle 
treated mice—††P < .01.  
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Figure 3.2  Effect of chronic nicotine, 24-hour withdrawal and the brain-derived 
neurotrophic factor (BDNF) Val66Met genotype on behavior in the marble burying 
task. Data represents the mean number of marbles buried over 15 minutes ± SEM from 
mice in the following groups: BDNFVal/Val; saline (n = 13), 24-hour withdrawal (WD)    
(n = 12) and BDNFMet/Met; saline (n = 11), 24-hour WD (n = 14). BDNFMet/Met mice bury 
more marbles at baseline compared with BDNFVal/Val saline-treated mice. In BDNFMet/Met 
mice 24-hour withdrawal from nicotine reduces the amount of marbles buried compared 
to saline-treated BDNFMet/Met mice, *P < .05.  
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Figure 3.3 Open field behavior in the brain-derived neurotrophic factor (BDNF) 
Val66Met variant during baseline (saline-treated) and 24-hour withdrawal. Open 
field parameters were measured over 30 minutes with data presented ± SEM in the 
following groups: BDNFVal/Val; saline (n = 9), 24-hour withdrawal (WD) (n = 10) and 
BDNFMet/Met; saline (n = 6), 24-hour WD (n = 7). A, BDNFVal/Val mice undergoing 24-
hour WD spend less time in the center compared to BDNFVal/Val saline-treated mice. B, 
Number of entries into the center is unchanged by genotype and treatment alone but 
displays a genotype by treatment interaction. C, BDNFMet/Met mice spend more time in the 
center for the first 5-minute time block compared to saline-treated BDNFMet/Met mice, 
while no difference in treatment on BDNFVal/Val mice is observed. D, No differences in 
total locomoter activity measured over a 30-minute time frame are seen between 
genotypes and treatment, *P < .05.  
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Figure 3.4 Western blot analysis of proBDNF and brain-derived neurotrophic factor 
(BDNF) prodomain in the hippocampus. A, Detection of proBDNF (~32kDa) 
expression in the hippocampus is reduced in BDNFMet/Met mice compared to BDNFVal/Val 
mice. Treatment with saline, 2 weeks of chronic nicotine (18mg kg−1 day−1) or 24-hour 
withdrawal does not alter proBDNF levels. B, BDNF prodomain (~15.5kDa) expression 
is decreased in hippocampal lysates of saline-treated and chronic nicotine-treated 
BDNFMet/Met mice compared to BDNFVal/Val mice. Following 24-hour withdrawal BDNF 
prodomain levels in BDNFMet/Met mice are increased. Representative blots are shown 
below each panel, bars represent mean ± SEM of proBDNF (A) and BDNF prodomain 
(B) densitometry data normalized to actin; n = 4 per group, *P < .05.  
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CHAPTER 4 
GENERAL DISCUSSION 
Tobacco kills half of the people that use it regularly, causing 5 million deaths a 
year worldwide (WHO, 2006). The detrimental effects of tobacco are not only a concern 
for the present but also of the future, with 1 billion tobacco-related deaths estimated to 
occur within the 21st century (WHO, 2006). Quitting smoking increases life expectancy, 
prevents smoking-related diseases and provides savings of ~$375,000 in healthcare costs 
(Hurley and Matthews, 2007). However, although 70% of smokers express a desire to 
quit, current therapies only achieve a 15% success rate after 3-months of treatment 
(Hughes et al., 2004; and, 2014). Withdrawal symptoms including anxiety, irritability, 
craving, and cognitive deficits are physiological and psychological barriers to a 
successful quit attempt (West et al., 2006). In addition, relief of these aversive symptoms 
through continued nicotine use acts as a negative reinforcement for smoking behavior. 
Multiple preclinical and clinical studies have explored the influence of targeting the 
primary receptors for nicotine (nAChRs) as cessation aid therapies. However, the limited 
success of these strategies calls for investigation outside of nAChRs to abrogate nicotine 
withdrawal symptoms. This dissertation explores the genetic and molecular mechanisms 
underlying nicotine withdrawal, in order to identify novel pharmacotherapies and/or 
personalized therapies for improved cessation rates. 
Our lab previously used CREB chromatin immunoprecipitation followed by 
whole genome sequencing (CREB ChIP-Seq) to identify “cell-to-cell signaling, 
carbohydrate metabolism, lipid metabolism” as a top gene network preferentially bound 
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by CREB following withdrawal from nicotine. Within this pathway, we found the 
energy-sensor molecule AMPK (AMP-activated protein kinase) to be dynamically 
regulated following chronic nicotine and withdrawal. In Chapter 2, we investigated the 
correlative and causative effects of changes in AMPK activation (pAMPK) on the 
behavioral phenotypes caused by nicotine withdrawal in mice.  
Our studies demonstrate biphasic effects on AMPK activation following chronic 
nicotine exposure and withdrawal. Chronic nicotine administration increased pAMPK 
expression in the hippocampus, but following 24-hour withdrawal pAMPK activation 
was diminished. In order to mechanistically examine the consequences of these changes 
in AMPK activation state on nicotine withdrawal symptoms, we utilized behavioral 
paradigms that reliably demonstrate the anxiety and cognitive impairments observed in 
humans following withdrawal. Our lab has documented the sensitivity and reproducibility 
of three preclinical behavioral paradigms: Novelty-Induced Hypophagia (NIH), Marble-
Burying (MB), and Fear Conditioning (FC). We hypothesized that by maintaining AMPK 
activation during withdrawal, we could ameliorate the anxiogenic behaviors observed in 
these behavioral paradigms following withdrawal. Using these behavioral models we 
evaluated the effects of maintaining pAMPK activation during withdrawal via the FDA 
approved diabetes drug metformin, a known activator of AMPK, or the direct AMPK 
activator AICAR. We demonstrated that AICAR and metformin, given for one week 
prior to withdrawal, maintained elevated levels of pAMPK in the hippocampus during 
withdrawal and attenuated anxiogenic behaviors following withdrawal from nicotine in 
the NIH and MB tests. Further, metformin given for one week prior to withdrawal from 
nicotine rescued the cognitive deficits associated with withdrawal. 
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In addition, we employed a complementary genetic approach to interrogate 
AMPK function in the CNS. Genetic loss-of-function studies in multiple model 
organisms have dramatically improved our understanding of the cause of many human 
diseases and yielded useful targets for therapeutic drugs. For this experiment, we utilized 
AMPKα1loxP/loxP;AMPKα2loxP/loxP mice (graciously provided by Dr. Benoit Viollet) that 
harbor conditional alleles for two essential AMPK subunits. Microinjection of adeno-
associated virus (AAV) expressing Cre recombinase (AAV-Cre) directly into the 
hippocampus of AMPKα1loxP/loxP; AMPKα2loxP/loxP mice resulted in site-specific deletion 
of AMPKα. The efficacy of metformin in reducing anxiety-like behaviors during 
withdrawal in the NIH test was reduced in mice lacking AMPKα in the hippocampus. 
These findings support the idea that metformin is working through AMPKα in the 
hippocampus to abrogate anxiety-like behavior following nicotine withdrawal. 
 In addition to studies examining the molecular underpinnings of nicotine 
withdrawal in Chapter 3, we investigated how single-nucleotide polymorphisms (SNPs) 
in genes involved in nicotine dependence influence the affective phenotypes of nicotine 
withdrawal. We employed a mouse model of a human genetic variant (Val66Met) in the 
BDNF gene, that substitutes a valine (val) for a methionine (met) amino acid (Val66met) 
and reduces activity-dependent secretion of BDNF (Egan et al., 2003). The Met/Met 
genotype is present in 5% of the US population (Shimizu et al., 2004), and has been 
independently associated with anxiety (Chen et al., 2006), depression (Tsai et al., 2010), 
and substance abuse (Hariri et al., 2003). We utilized the BDNF Val66Met mouse model 
to examine the effects of this polymorphism on mediating anxiety-like behavior 
following withdrawal from nicotine.  
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 Remarkably we discovered reduced withdrawal phenotypes in BDNFMet/Met mice. 
Furthermore, we found that the decrease in anxiety-like behavior in the BDNFMet/Met mice 
correlated with an increase in the BDNF prodomain. The prodomain is a peptide that 
remains following protealytic cleavage of the precursor proBDNF into the mature form of 
BDNF (mBDNF). This prodomain peptide is biologically active and secreted from 
neurons in an activity-dependent manner, but is decreased in naïve BDNFMet/Met mice 
(Anastasia et al., 2013). Thus, withdrawal reverses the deficits in the BDNF prodomain 
observed in these mice and suggests that the Met66 prodomain might be a novel, active 
ligand that can contribute to reducing the anxiety-like behavior in mice following 
withdrawal from nicotine. 
 Together, this thesis examined molecular and genetic mechanisms underlying the 
affective and cognitive impairments induced by nicotine withdrawal. From these findings 
as many new questions arose as were answered. The following discussion will explore 
these questions, highlighting potential areas of research that could expand upon the 
results reported here, and further our pursuit of novel pharmacotherapies and/or 
personalized therapies for improved smoking cessation rates.  
 
Potential upstream kinases for nicotine and metformin activation of AMPK 
In our first study we identified a novel role for the energy sensor molecule AMPK 
in the brain. However, one large question that remains from Chapter 2 is which 
mechanism activates AMPKα during chronic nicotine and if this mechanism is involved 
in activating AMPKα following administration of metformin during withdrawal. A 
further understanding of the complete pathway that contributes to metformin efficacy in 
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mediating withdrawal symptoms might provide greater target specificity for novel 
cessation drugs.  
Activation of AMPK can occur through two independent upstream kinases; the 
tumor suppressor liver kinase B1 (LKB1), and the calcium/calmodulin-dependent protein 
kinase kinase-β (CAMKKβ) (Woods et al., 2003; Lizcano et al., 2004; Hawley et al., 
2005; Woods et al., 2005). Either of these kinases could be responsible for activating 
AMPK during chronic nicotine and/or following metformin treatment.  
LKB1 phosphorylates AMPKα at the Thr172 residue in vitro and in vivo in 
response to increases in the AMP:ATP ratio (Shaw et al., 2004). Only one study has 
examined the effect of nicotine on the LKB1/AMPK pathway in the brain, finding no 
difference in LKB1 levels in the hypothalamus following chronic nicotine administration 
(de Morentin et al., 2012). Further, conditional ablation of LKB1 in the cortex elicited no 
changes in pAMPK or total AMPK levels, suggesting a limited role of LKB1 in this brain 
region (Barnes et al., 2007). Our study showed increased AMPK activation in the 
hippocampus following nicotine. However, nicotine decreases AMPK activity in the 
hypothalamus (de Morentin et al., 2012), signifying a bidirectional effect of nicotine on 
pAMPK in a brain-region specific manner. Due to this region-specificity for AMPK 
activation or suppression following nicotine, it is possible that the effect of LKB1 
activation in the hippocampus is independent from its effects within the cortex and 
hypothalamus. It is also important to understand if metformin can maintain elevated 
levels of AMPK following nicotine withdrawal through activation of LKB1. Metformin 
is an established activator of LKB1, and increases AMPK activation by increasing the 
physical association of AMPK with LKB1 in vivo (Zou et al., 2004). Future studies are 
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needed to confirm if metformin activates LKB1 in the hippocampus following nicotine 
withdrawal.   
CAMKKβ (also known as CAMKK2) shares similar homology to LKB1 and 
phosphorylates AMPKα at the same threonine residue (Thr172) (Hawley et al., 2005; 
Hurley et al., 2005; Woods et al., 2005). Contrary to LKB1, CAMKKβ is stimulated by 
changes in intracellular calcium, independent of changes in AMP (Edelman et al., 1996). 
To date, no studies have investigated the role of the CAMKKβ/AMPK pathway 
following nicotine exposure or withdrawal from nicotine. However, nicotine increases 
intracellular Ca2+ within the hippocampus through activation of voltage-gated Ca2+ 
channels, resulting in an influx of extracellular Ca2+ (Barrantes et al., 1995). The 
permeability of neuronal nAChR’s to calcium also contributes to increased intracellular 
Ca2+ (Sands and Barish, 1991). The nicotine-induced rise in intracellular Ca2+ might 
regulate CAMKKβ and thus activation of AMPK. There is no direct evidence of 
metformin activating AMPK through CAMKKβ. Metformin can, however, regulate Ca2+ 
as demonstrated by its ability to reduce phenylephrine-induced influxes of Ca2+ in a dose-
dependent manner within hepatocytes (Ubl et al., 1994). It is of interest to see if this 
mechanism occurs in neuronal cells, and if metformin modulation of Ca2+ signaling alters 
the CAMKKβ/AMPK pathway. 
 
Mitochondria ~ could the cell’s powerhouse be contributing to withdrawal? 
As discussed in Chapter 2, one of the top networks altered following nicotine 
withdrawal included AMPK, a kinase with a central role in energy metabolism. As the 
cells “powerhouse”, mitochondria play a central role in energy metabolism. The central 
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nervous system exhibits very high energy demand, and although the brain only represents 
2% total body mass it consumes approximately 25% of the body’s energy at rest. High-
energy metabolism is directly coupled to neuronal activity, and even a slight deregulation 
of this system can have detrimental effects. Recent novel insights have linked energy 
metabolism deficits to the pathology of multiple neuronal diseases including depression 
(Gardner, 2003), bipolar disease (Stork and Renshaw, 2005) and Alzheimer’s disease 
(Castellani et al., 2002).  
As the major energy sensor within the cell, AMPK monitors energy status and 
maintains its homeostasis through downstream modulation of pathways that maintain 
mitochondrial function. Adenine nucleotides including AMP and ADP bind to the ϒ 
subunit of AMPK leading to a conformational change that promotes activation 
(phosphorylation) of AMPK while also inhibiting dephosphorylation at Thr172 (for review 
see (Hardie, 2011)). The promotion of AMPK activity through adenine nucleotides 
allows for direct regulation of AMPK via changes in energy metabolism/mitochondria 
function. Therefore, any drug that alters the ratio of AMP:ATP within the brain could 
work to activate AMPK through this manner.  
Nicotine can penetrate mitochondria and modulate their function. Cigarette smoke 
in vitro induces inner membrane damage in mouse brain mitochondria (Yang and Liu, 
2003), and significantly decreases mitochondrial complex IV activity (Woynillowicz et 
al., 2012). In vivo studies also support an effect of nicotine on mitochondria. For 
example, mice administered chronic nicotine exhibit decreased complex I (respiration) 
activity (Cormier et al., 2003). Specifically within the hippocampus, chronic nicotine 
modulates 28 genes in the mitochondria, including ones with central roles in the electron 
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transport and respiratory chain (Wang et al., 2009). These findings suggest that 
mitochondria might be a direct target and regulator of nicotine-induced neuronal changes. 
Furthermore, it is possible that the changes in energy metabolism occurring from the 
influence of nicotine on mitochondrial function might be activating AMPK secondarily.  
 In addition to physical and transcriptional changes that could alter mitochondrial 
function and activate AMPK, nicotine might also be activating AMPK through reactive 
oxygen species formed when mitochondrial respiration is blocked. Nicotine can generate 
reactive oxygen species (ROS) in the brain (Bhagwat et al., 1998) and nicotine-induced 
oxidants can activate AMPK (An et al., 2007) through a mechanism that is still unclear. 
To date, only one study has attempted to causally link mitochondrial dysfunction/ROS to 
the anxiety-like behavior observed during nicotine withdrawal in mice. This study 
showed that an antioxidant found in pecan nut shells reduced the oxidative damage 
caused by cigarette smoke and attenuated the anxiety-like behavior observed following 
withdrawal in mice (Reckziegel et al., 2011), highlighting an anxiolytic role of 
antioxidants in withdrawal therapy. In our studies we found that AMPK activation within 
the hippocampus attenuated anxiety-like behavior during withdrawal. Increases in 
oxidative stress within the hippocampus elevate anxiety-like behavior (de Oliveira et al., 
2007) in rats, whereas attenuation of oxidative stress following antioxidant treatment 
attenuates anxiety-like behavior (Patki et al., 2015). As nicotine increases ROS, and 
antioxidants are known activators of AMPK (Cao et al., 2014b), the unifying mechanism 
for mediation of behavior during nicotine withdrawal could be by AMPK modulating 
ROS and improving mitochondrial function following nicotine withdrawal.  
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Similar to nicotine, metformin is also an inhibitor of complex I of the 
mitochondria (Owen et al., 2000). This inhibition disrupts energy production leading to 
an altered ratio of AMP:ATP and subsequent activation of AMPK in an attempt to regain 
energy homeostasis. Contrary to nicotine, metformin can act as an anti-oxidant agent, 
reducing reactive oxygen species (ROS) production in the brain. This reduction 
attenuates learning and memory deficits following a high-fat diet (Pintana et al., 2012). 
Future studies should identify if targeting molecules such as AMPK that are functionally 
linked to improving energy balance through mitochondrial function might provide further 
insight into the mechanisms of metformin and its behavioral effect on withdrawal from 
nicotine.  
 
Metformin for smoking cessation ~ looking beyond affect and cognition  
The use of metformin for smoking cessation is unique as its potential extends 
beyond improving mood and cognition during withdrawal. In addition to its repurposing 
potential for nicotine cessation, metformin’s primary indication as an antihyperglycemic 
drug for the treatment of type 2 diabetes might also prove beneficial in the treatment of 
withdrawal from nicotine. In 2014 the Surgeon General added a new finding indicating 
that smoking is a cause of type 2 diabetes (U.S. HHS, 2014). There is a 44% increased 
risk of developing type 2 diabetes with smoking (Lycett et al., 2015) and over 20 
publications supporting this connection (for review see (Willi et al., 2007)). Nicotine 
exposure promotes insulin resistance, a key factor in type 2 diabetes (Epifano et al., 1992; 
Targher et al., 1997; Assali et al., 1999). The association between smoking and type 2 
diabetes is dose-dependent, with the amount of cigarettes smoked directly correlating to 
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the impact on insulin sensitivity (Targher et al., 1997) and prevalence of pre-diabetes 
(Aeschbacher et al., 2014). Higher nicotine dependence, as measured by the Fagerstrom 
questionnaire, is also associated with prevalence of pre-diabetes during smoking 
(Aeschbacher et al., 2014). Increases in oxidative stress (Reddy et al., 2009), 
inflammation (Yeh et al., 2010), adiposity (Fujimoto et al., 1990) and mTOR activation 
(Bergman et al., 2012) are all co-associated with nicotine and type 2 diabetes. 
Nonetheless, a true causative interaction has yet to be identified. As AMPK plays a 
critical role in all of these processes, it is of interest to further dissect out its role in the 
deterioration of glycemic control following smoking.  
Smoking cessation does not immediately eliminate the risk of diabetes as it takes 
anywhere from 3 to 20 years to reduce the incidence of diabetes to the levels of non-
smokers (Assali et al., 1999; Wada et al., 2007). Not only is the risk prolonged but eight 
studies have showed an increased risk (14-54%) of developing diabetes in the first few 
years after a quit attempt (Lycett et al., 2015). Of interest, these studies did not take into 
account that smoking cessation treatments might be influencing the risk. Long-term use 
of nicotine gum (>11 months) is associated with hyperinsulinemia and insulin resistance 
(Eliasson et al., 1996). Isolation of nicotine as the bioactive compound responsible for 
metabolic dysfunction suggests that nicotine replacement might maintain the risk of 
diabetes that is initiated through smoking. This concern also applies to cessation therapies 
such as varenicline that act by mimicking nicotine at nicotinic receptors. Functional 
nicotinic receptors are located on pancreatic beta cells (Yoshikawa et al., 2005). Nicotine 
can bind to pancreatic islets and inhibit glucose-induced insulin release following both 
acute and chronic exposure in rats and humans (Yoshikawa et al., 2005). Therefore, it 
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could be hypothesized that drugs such as varenicline that activate nicotinic receptors 
could mimic the mechanisms of nicotine and decrease insulin sensitivity following 
smoking in humans. In support of this notion, following 48-hours of treatment with 
nicotine, varenicline, or bupropion in vitro, glucose-stimulated insulin secretion is 
decreased across all treatment groups (Woynillowicz et al., 2012). This decrease was 
seen at drug concentrations lower than those reported in clinical pharmacokinetic studies 
and raises the concern for how current cessation therapies might be increasing the 
diabetes risk. 
Although it is clear that smoking and insulin sensitivity are correlated, the use of 
diabetic drugs to manage glucose levels during smoking and following withdrawal has 
only recently emerged. There is only one study that examined the effect of metformin and 
smoking in a type 2 diabetic population. Ex-smokers who were not treated with 
metformin had a 19% higher mortality risk than those who were treated with metformin, 
with authors concluding that metformin should be given as a treatment to current and ex-
smokers with type 2 diabetes (Paul et al., 2015). Studies such as this one highlight the 
need for an antidiabetic agent, such as metformin, for smoking cessation independent of 
its potential effects on mood and cognition during nicotine withdrawal. 
 In Chapter 3, we highlighted the role of genetic variants in nicotine withdrawal 
symptoms. Of functional relevance, genetic variants in nAChRs can also influence type 2 
diabetes. Genetic variants in four nicotinic receptor subunit genes: CHRNA3, CHRNA5, 
CHRNB2, CHRNB4 jointly contribute to an increase in the susceptibility to type 2 
diabetes (Yang et al., 2012). Variants in the enzyme that metabolizes nicotine, CYP2A6 
also influence the risk of type 2 diabetes, with heavy smokers that are poor nicotine 
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metabolizers exhibiting a significantly increased risk of type 2 diabetes (Liu et al., 2011).  
Our study in Chapter 3 was the first to use mouse models of human SNPs to investigate 
nicotine withdrawal in a preclinical model. It would be of interest to extend our findings 
and to use these preclinical models to begin exploring the complex interaction of 
nicotine, smoking, and diabetes.  
 
The effect of current therapies on AMPK? 
Combination pharmacotherapies for nicotine withdrawal are commonly used in 
the clinic and are often more effective then monotherapies (Jorenby et al., 1999; Ebbert et 
al., 2014; Koegelenberg et al., 2014). In order to consider metformin clinically as an add-
on drug for nicotine cessation, it would be important to determine in a preclinical model 
if AMPK is also activated by current smoking cessation therapies. As mentioned in the 
introduction, there are currently two cessation pharmacotherapies other then remedial 
administration of nicotine that increase abstinence rates: varenicline and bupropion. 
Effective cessation therapies can include a combination of drugs that work synergistically 
on the same pathway such as varenicline and nicotine replacement therapy, both nAChR 
agonists (Koegelenberg et al., 2014). The effectiveness of combination therapies can also 
be attributed to targeting multiple pathways with distinct drug mechanism of actions, 
such as varenicline and bupropion polytherapy (Ebbert et al., 2014). Therefore, regardless 
of whether or not varenicline and bupropion activate AMPK it is of interest to determine 
if an additional therapy engaging AMPK activation, such as metformin, during 
withdrawal would have a synergistic or additive effect with current therapies on 
withdrawal behavior in mice. These effects will be reflected in behavior with metformin 
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combination therapy enhancing the affective and cognitive effects of either NRT, 
varenicline or bupropion treatment given alone.  
 
Concluding Remarks 
Future directions for these studies include preclinical and clinical experiments. 
Proven preclinical efficacy of metformin in alleviating withdrawal symptoms along with 
its established safety profile would encourage investigators to translate these studies into 
future clinical trials for higher continuous abstinence rates with metformin mono or 
combination therapy. To this end, our lab in collaboration with the Center for 
Interdisciplinary Research on Nicotine Addiction (CIRNA) are initiating a double-blind 
placebo-controlled within-subjects crossover design pilot to investigate the effect of 
metformin on smoking cessation. The end points for this study will include subjective 
measures (mood, craving, withdrawal), and cognitive testing during 24-hour withdrawal 
following a low dose of metformin, high dose of metformin, or placebo. As highlighted 
in this discussion it would be of interest to also include endpoint measurements of insulin 
sensitivity such as fasting plasma insulin and glucose levels, as well as C-peptide, a 
clinical measurement of endogenous insulin secretion (Jones and Hattersley, 2013) 
In addition to clinical trials, preclinical studies should begin to use animal models 
of genetic variants to understand the relationship between glycemic control and 
smoking/smoking cessation. Animal models can also continue to identify the mechanisms 
through which AMPK is eliciting behavioral phenotypes during nicotine withdrawal 
including investigation of upstream activators of AMPK, and potential downstream 
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pathways. Elucidating these mechanisms could contribute to greater drug specificity for 
smoking cessation and overall improved cessation therapies for nicotine withdrawal.  
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Abstract 
The cAMP response element (CRE)-binding protein, CREB, is a transcription factor 
whose activity in the brain is critical for long-term memory formation. Phosphorylation 
of Ser133 in the kinase-inducible domain (KID), that in turn leads to the recruitment of 
the transcriptional coactivator CREB-binding protein (CBP), is thought to mediate the 
activation of CREB. However, the importance of phosphorylation for CREB binding to 
DNA and subsequent gene transcription in vivo is controversial. To definitively address 
the role of CREB phosphorylation in gene transcription and learning and memory, we 
derived mutant mice lacking the Ser133 phosphorylation site. These mice exhibit normal 
CREB-mediated gene transcription for a number of genes implicated in learning and 
memory processes. Furthermore these mice have no deficits in hippocampus- or striatum-
dependent learning. Strikingly, our findings show that CREB phosphorylation at Ser133 
is not necessary for CREB binding to CRE sites, CREB-mediated transcription, or 
CREB-mediated behavioral phenotypes associated with learning and memory.  
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Introduction 
The cyclic AMP response element (CRE)-binding protein, CREB, is a member of 
a family of structurally related transcription factors that bind to conserved cAMP 
response element (CRE) sites. CREB binds to over 30,000 CRE sites and regulates >5000 
target genes, roughly one quarter of the human genome (Impey et al., 2004; Zhang et al., 
2005), and plays a critical role in learning, memory, addiction, and depression (Carlezon 
et al., 2005; Blendy, 2006). It has long been held that the critical event in the activation of 
CREB is phosphorylation of Ser133 in the kinase-inducible domain (Gonzalez and 
Montminy, 1989; Gonzalez et al., 1991). As CREB phosphorylation can result from the 
activation of multiple signaling cascades, including phosphorylation by protein kinase A, 
protein kinase C, and calmodulin kinases, this event has been proposed as a mechanism 
for the convergence of these signaling pathways (Brindle and Montminy, 1992; Sassone-
Corsi, 1995). Converging evidence from Aplysia, Drosophila, mice, and rats indicates 
that CREB is critical for long-term memory formation (Yin and Tully, 1996; Silva et al., 
1998; Carlezon et al., 2005). In particular, CREBαΔ and CREBIR mutant mice exhibit 
deficits in contextual and cued fear learning, while viral overexpression of CREB leads to 
enhanced fear learning (Bourtchuladze et al., 1994; Josselyn et al., 2001; Graves et al., 
2002; Kida et al., 2002; Restivo et al., 2009). Similarly, alterations in CREB activity also 
lead to bidirectional effects on spatial memory performance (Sekeres et al., 2010). 
Furthermore, alterations in CREB expression are accompanied by alterations in cell 
excitability, synaptic plasticity, hippocampal neurogenesis, and neuronal survival (Barco 
et al., 2002; Nakagawa et al., 2002; Fujioka et al., 2004; Marie et al., 2005; Dong et al., 
2006; Gur et al., 2007; Suzuki et al., 2011). Because of the proposed critical role for 
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CREB phosphorylation in the pathway activation outlined above, we investigated 
whether CREB phosphorylation at Ser133 is indeed necessary for fear learning. To this 
end, we derived a mouse with a single point mutation that prevents CREB 
phosphorylation at Ser133 and evaluated these mice for defects in both hippocampus- and 
striatum- dependent learning. Additionally, we examined whether CREB- mediated gene 
transcription was altered in the phospho mutant mice either at baseline or following 
learning. Remarkably, we find that CREB phosphorylation at Ser133 is not required for 
any of these processes.  
 
Materials & Methods  
Derivation of CREB S133A mice  
A 15.1-kb DNA fragment, containing exon 7 of the Creb1 gene, was retrieved from 
C57BL/6J mouse BAC clone RP23-31C24 via bacterial recombination (Copeland et al., 
2001). The TCC sequence within exon 7 encoding S133 was mutated to GCC (S133A) 
by site-directed mutagenesis and cloned into the retrieved genomic sequence. A silent 
mutation of CCT to CCC in the P132 codon was also included in order to disrupt a StuI 
restriction enzyme site. The self-excising selection cassette based on (Bunting et al., 
1999), with the exception of the replacement of the PollI promoter with the PGK 
promoter to allow for kanamycin resistance in bacteria, was also inserted 5’ of the 
mutated exon 7 to complete the targeting vector. The linearized targeting vector was 
electroporated into C57BL/6J-derived ES cells (Chemicon), and clones surviving G418 
selection were screened for homologous recombination by Southern blot analysis. 
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Targeted clones were injected into C57BL/6J-derived blastocysts that were then 
transferred to pseudopregnant females. Male offspring were mated to C57BL/6J females 
and ES cell-derived offspring, heterozygous for the S133A allele, were identified by 
PCR-based genotyping. Additional genotyping for sequences within the selection cassette 
was performed to ensure that proper and complete recombination between the loxP sites 
had occurred in the male germline. The sequence of the genotyping primers are as 
follows: forward: AGGGCATGGCAGTACATAG; reverse: CATGTGCTTTCCTCCAT 
GTG. Mice were backcrossed at least five generations with C57BL/6 to eliminate any 
potential mutations carried by the ES cells. CREBαΔ mutant mice and wild-type 
littermates were bred and maintained on a F1 hybrid background (129SvEvTac/ 
C57BL/6NTac) as described previously (Walters and Blendy, 2001). All animals were 
housed in a temperature and humidity controlled animal care facility with a 12 h 
light/dark cycle (lights on at 7:00 a.m.). All procedures were approved by the University 
of Pennsylvania Animal Care and Use Committee. Equal numbers of male and female 
mice were utilized for all experiments. No significant sex differences were seen in any of 
the behavioral or molecular assays and therefore the data from both sexes are combined 
in all analyses.  
 
Fear conditioning  
Briefly, mice were placed in a rectangular (16 in length × 6 1/4 in width × 8 3/8 in 
height) fear-conditioning chamber (Med Associates) and presented with two tone (85 dB, 
2 kHz)/footshock (0.7 mA) pairings. The mice were given 2.5 min to explore the box 
prior to the onset of the first tone (conditioning stimulus; CS), which preceded the 2-sec 
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footshock by 28 sec. The second pairing occurred 1 min later and the mice were removed 
from the chamber after 5 min. The chamber was washed with 70% ethanol between 
animals. Mice were tested for context conditioning in the same chamber at 24 h after 
training. For context testing, mice were placed into the unaltered chamber for 5 min. For 
testing of cued conditioning, the floor and sides were replaced with smooth, black panels. 
During the cued test, a water solution containing 1% orange extract was placed on a 
cotton ball underneath the floor and between subjects the chamber was wiped down with 
this mixture. The fan was disconnected. For cued testing, the mice were placed in the 
altered chamber for 5 min in total, and they were exposed to the CS for the last 3 min. 
Mice that were tested for contextual conditioning at 24 h after training were then tested 
for cued conditioning 1 h later. Freezing behavior was assessed with FreezeScan analysis 
software (Clever Sys) and confirmed by hand scoring the data. A separate group of mice 
was exposed to contextual fear conditioning alone without any presentation of tones 
during training. A separate group of mice was trained on fear conditioning to generate 
tissue for RT-PCR experiments. 
 
Shock sensitivity  
To determine whether CREB S133A mice exhibit alterations in shock sensitivity that 
might be masking effects on the fear conditioning behavior, we exposed mice to a range 
of 2-sec foot shocks (0.10 – 0.80 mA) over a 20-min testing period. There were three 
presentations of each shock intensity, with a 20-sec inter- stimulus interval and a 90-sec 
intertrial interval. We scored the animals response for each shock presentation (0 = no 
response, 1 = flinch, 2 = vocalization, 3 = run, 4 = jump) and averaged the three 
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responses at each shock intensity (scoring adapted from (Gulick and Gould, 2009)).  
 
Instrumental learning  
Mice were placed in operant chambers (Med Associates) and trained to spin a wheel 
manipulandum to receive a sucrose pellet. A compound cue stimulus consisting of a cue 
light above the active lever, a 2900-Hz tone, and house light off was concurrent with each 
pellet administration, followed by an additional 8-sec time-out when responding had no 
programmed consequences and the house light remained off. Mice were allowed to self-
administer a maximum of 50 pellets per 60 min operant session. During these 
experiments, mice were food restricted to ~90% of their free-feeding weight. The average 
percent active responding was calculated for 3 d after 7 d of training.  
 
Western blot  
Mice were taken directly from their home cages and killed by cervical dislocation. Whole 
hippocampi were dissected and frozen in liquid nitrogen. Tissue was homogenized in 
200mL of ice-cold extraction buffer containing PBS, 1 mM EGTA, 1 mM EDTA, 0.01% 
SDS, and 1 mM PMSF. Protein concentration was quantified using the Pierce BCA 
Protein Assay Kit (Thermo Scientific). Equal amounts of protein (30 µg for whole cell) 
were loaded and separated in 10% polyacrylamide Tris–Glycine gels (Invitrogen) and 
transferred to nitrocellulose membranes using the i-Blot dry transfer system (Invitrogen). 
Membranes were blocked with Li-Cor blocking buffer. Membranes were incubated for 
24h at 4°C with selective antibodies to: CREB (1:1000; Santa Cruz), pCREB (1:1000, 
Millipore), TORC1 (1:1000, Cell Signaling), and GAPDH (1:2000, Cell Signaling). 
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Membranes were then incubated with fluorescent secondary antibodies (1:5000, IR-dye 
680 or IR-dye 800), before being imaged on an Odyssey fluorescent scanner (Licor 
Biosciences). GAPDH was used as an internal loading control.  
 
RNA extraction, cDNA synthesis, and quantitative real-time polymerase chain 
reaction  
Mice were killed by cervical dislocation directly from their home cages or 30 min 
following fear-conditioning training for the evaluation of early gene expression changes. 
Brains were rapidly removed, whole hippocampi hand-dissected, and frozen in liquid 
nitrogen. RNA was extracted from hippocampal tissue using TRIzol/chloroform 
(Invitrogen) and the RNeasy Mini kit (Qiagen). cDNA was synthesized from RNA using 
an oligo(dT) primer (Operon) and Superscript II reverse transcriptase (Invitrogen). 
Quantitative real-time polymerase chain reaction (QPCR) was carried out using the 
SYBR-green master mix (Applied Biosystems) and 300 nM primers (final concentration) 
on the Stratagene MX3000 using MXPro QPCR software. Cycling parameters were 95°C 
for 10 min followed by 40 cycles of 95°C (30 sec) and 60°C (1 min), ending with a 
melting curve analysis to assess the amplification of a single amplicon. All reactions were 
performed in triplicate, with the median cycle time used for analysis. TATA-box binding 
protein (TBP) was used as a housekeeping gene against whose levels all experimental 
genes were normalized. Primer sequences can be found in Appx. Table 1.  
 
Chromatin immunoprecipitation  
Macrodissected brain tissue was chopped and suspended in 1.1% formaldehyde/PBS for 
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10 min at room temperature with constant agitation. Cross-linking was quenched by the 
addition of glycine to a final concentration of 0.125 M, after which the tissue was 
sedimented by centrifugation. Pellets were resuspended in ChIP cell lysis buffer (10 mM 
Tris–HCl, pH 8.0, 10 mM NaCl, 3 mM MgCl2, 1% NP-40, protease inhibitors) and 
dounce homogenized (Kontes, 18 × 150-mm tube reservoir; 8 × 220-mm pestle shaft). 
Chromatin was sonicated to an optimal 200-bp fragment size using a Diagenode 
Bioruptor for five cycles (5 min; 30-sec on, 30-sec off). Insoluble debris was removed by 
centrifugation at 13,000g for 15 min at 4°C, supernatant was collected and flash-frozen in 
liquid nitrogen. Cross-linking was reversed by the addition of NaCl to a final 
concentration of 192 mM, overnight incubation at 65°C, and purification using a PCR 
purification kit (Qiagen). Immunoprecipitations were performed as previously described 
(Friedman et al. 2004) with anti-CREB (sc-186, Santa Cruz), anti-trimethyl-Histone H3 
(Lys4) (07-473, Millipore), or control IgG (sc-2025, Santa Cruz) antibodies. Promoter 
enrichment was quantified using QPCR and calculated by comparing the difference in 
abundance of the control DNA amplicon (18S rRNA loci) to the amplicon sequence of 
interest (cfos, fosB, or GAPDH) in genomic DNA (input) to the immunoprecipitated 
DNA. Data were analyzed using a two-way ANOVA with Bonferroni/Dunn post hoc test. 
Primer sequences are available upon request.  
 
Microarray  
RNA samples were labeled with the Agilent low input labeling kit in single-color mode. 
The resulting cRNA was then hybridized overnight to Agilent 4x44K Mouse Whole 
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Genome v2 arrays. The arrays were scanned with an Agilent scanner and the resulting 
images processed with Agilent’s Feature Extraction program (v10.10.1.1). The 
gNetSignal data values were then quantile-normalized (R package limma, 
normalizeBetweenArrays function) and statistical significance of differential expression 
assessed with the SAMR package.  
 
 
Results 
To specifically examine the functional role of CREB phosphorylation, we derived 
mutant mice with a single point mutation in exon 7 at Ser133 to prevent phosphorylation 
at this site (Appx. 1A). We analyzed homologous recombination and germline 
transmission of the mutant allele by DNA sequencing of homozygous mutant mice, 
confirming the presence of the Ser133Ala mutation (Appx. 1B). It should be noted that 
previous attempts to generate similar mice resulted in splicing around the minigene in the 
absence of Cre, preventing a true assessment of the contribution of the Ser133Ala 
mutation to mouse physiology and behavior (Wingate et al., 2009). Control mice in the 
current study produce normal amounts of “only” wild-type protein, allowing for the 
appropriate comparisons to be made. Next, we examined the effect of the Ser133Ala 
mutation on CREB phosphorylation by Western blot analysis. As predicted, we detected 
an immunoreactive band at 43 kDa corresponding to phosphorylated CREB in the 
hippocampus of wild-type mice, but not in Ser133Ala homozygous mutant mice (Appx. 
1C,D). To assure that the Ser133Ala mutation did not alter levels of total CREB, we 
examined CREB protein expression by Western blot analysis. In contrast to the reduced 
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levels of CREB protein seen in CREBαΔ mutant mice (Blendy, 2006), we found no 
differences in total CREB immunoreactivity between wild-type and Ser133Ala mice 
(Appx. 1E). Following deletion or reduced expression of CREB, expression of CREM is 
up-regulated in multiple models (Hummler et al., 1994; Mantamadiotis et al., 2002; 
Gundersen et al., 2013; Shin et al., 2014), and provides partial functional compensation 
for the loss of CREB, as phenotypes are often more severe after deletion of both CREB 
and CREM (Mantamadiotis et al., 2002; Lemberger et al., 2008). To determine whether 
the Ser133Ala mutation also causes activation of the CREM gene, we examined CREM 
expression (utilizing a primer that targets all isoforms) in the hippocampus of Ser133Ala 
homozygous mutant mice. Unlike in CREBαΔ mutant mice, in which CREM mRNA is 
fivefold higher than in controls mice, no increase in CREM mRNA levels occurred in 
Ser133Ala mice (Appx. 1F). Furthermore, ICER, the primary isoform of CREM in the 
brain (Molina et al., 1993), was not up regulated in Ser133Ala mice either (Appx. 1G).      
Analysis of 473 offspring from heterozygous Ser133Ala matings revealed only a 
38% allelic frequency of the mutant allele (Appx. 1H) as opposed to the expected 50%, 
similar to the 42% frequency seen in CREBαΔ mutant mice (Hummler et al., 1994). A x2 
analysis revealed that these proportions are significantly different from the expected 
Mendelian frequencies [x2 (2,N = 473) = 54.69, P < 0.0001]. Similar to CREBαΔ 
mutants, this deviation was driven by a decrease in the proportion of animals containing 
two mutant alleles (11% Ser133Ala/Ser133Ala versus 35% +/+). These data suggest that 
CREB phosphorylation contributes to pre- or perinatal survival, but is not critical as 
many homozygous mutant mice survive, in contrast to CREB null mice, which die 
immediately after birth from respiratory distress (Rudolph et al., 1998).  
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To ascertain the effects of CREB phosphorylation on learning and memory, we 
chose fear conditioning, because this behavioral task has been clearly identified as 
CREB-dependent within our laboratory, whereas tasks like the Morris water maze have 
yielded inconsistent results (Bourtchuladze et al., 1994; Gass et al., 1998; Graves et al., 
2002). We found no genotype differences in foot shock sensitivity (FGENOTYPE (1,18) = 
0.078, P = 0.78; Appx. 2A) or in freezing behavior during training (FGENOTYPE (1,33) = 
0.872, P = 0.36; Appx. 2B). Furthermore, no effect of genotype was seen on either 
contextual or cued fear memory (context: t(16) = 0.52, P = 0.88, N = 9; cued: t(19) = 0.59, P 
= 0.56; Appx. 2C,D).  
Together with fear learning, disruption of CREB function has also been 
implicated in striatal-dependent learning (Pittenger et al., 2006; Lee et al., 2008). 
Therefore, we used an operant learning task, which requires mice to discriminate between 
active and inactive operant manipulanda. While CREBαΔ mutant mice exhibited deficits 
in discrimination learning compared with wild-type mice, no effects of the Ser133Ala 
mutation was seen in this paradigm (F(3,96) = 11.80, P < 0.0001 for the CREBαΔ mutant 
mice, Appx. 2C). Furthermore, despite the different background strains, no differences 
were seen between the F1 hybrid and C57BL/6 wild-type mice. These results 
demonstrate that when levels of CREB protein are constant, CREB phosphorylation at 
Ser133 is not necessary for hippocampus- or striatum-dependent learning tasks.  
Traditionally, it has been supposed that CREB is constitutively bound to CRE 
sites but no gene transcription will occur until the protein is phosphorylated (Dash et al., 
1991; Matthews et al., 1994). However, recent evidence suggests that CREB 
	  
	  
107	  
phosphorylation may be necessary for optimal CRE binding (Cha-Molstad et al., 2004). 
To determine whether CREB binding occurs in the absence of Ser133 phosphorylation, 
we performed chromatin immunoprecipitation (ChIP) of CREB in hippocampal lysates 
from naïve wildtype and Ser133Ala mice. Strikingly, we found strong CREB occupancy 
at the promoter regions of cfos and FosB in both wild-type and Ser133Ala mice (Appx. 
3A,B). To determine whether the association of CREB with these promoters was 
indicative of transcriptional activation, we performed ChIP for H3K4me3 and found it 
enriched to the same extent at the cfos and FosB promoters in both wild-type and 
Ser133Ala mice (Appx. 3C,D). H3K4me3 binding is associated with transcriptionally 
permissive chromatin (Lauberth et al., 2013) and cfos mRNA is also up-regulated (Appx. 
3G), thus confirming that CREB phosphorylation is not necessary for CREB-mediated 
transcription of this well-characterized CREB target gene. Additionally, we analyzed a 
region of the GAPDH promoter that does not contain CREB binding sites. Binding to this 
fragment was <20% of that detected for the cfos promoter, consistent with what has been 
reported previously for this gene/promoter region (Impey et al., 2004; Wisniewska et al., 
2010).  
To evaluate this notion further, we examined the ability of fear conditioning to 
induce expression of known CREB-target genes that play a role in this behavior (Hawk et 
al., 2012). In contrast to what is seen in CREBαΔ mutant mice, fear conditioning caused 
normal up-regulation of Nr4a1 (Appx. 3E), Nr4a2 (Appx. 3F), and cfos (Appx. 3G) 
expression in Ser133Ala mice, comparable to what was seen in both F1 hybrid (CREBαΔ 
wild type) and C57/ Bl6 (S133 wild-type) mice.  
Last, to determine whether phosphorylation-independent CREB-gene 
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transcription was limited to genes involved in fear memory behavior, we performed 
microarray expression profiling, comparing the mRNA transcriptome from naïve wild 
type and Ser133Ala total hippocampal lysates (N = 3-4). Among the 44,000 probe sets 
analyzed by the array, none were downregulated even with the low threshold of a 10% 
false discovery rate (FDR) (Appx. 3H).  
  
 
Discussion 
Taken together, we derived a novel mouse model homozygous for a CREB serine 
to alanine mutation, preventing phosphorylation at this site. Despite the extensive 
literature showing that stimulation of CRE-mediated transcription by CREB correlates 
with phosphorylation of CREB at Ser-133, our data demonstrate clearly that, with respect 
to learning and memory, CREB phosphorylation at Ser133 is not necessary for CREB 
binding to CRE sites, CREB-mediated transcription, or CREB-mediated behavioral 
phenotypes.  
Fear learning and memory has been firmly established as dependent upon CREB, 
both in our laboratory and others (Bourtchuladze et al., 1994; Kogan et al., 1997; Graves 
et al., 2002). The prior observations that increase in CREB Ser133 phosphorylation 
following fear conditioning correlate with changes in gene expression have led to the 
widely held belief that CREB phosphorylation must be required for these molecular and 
behavioral responses. Our novel mouse model enabled us to test this notion directly and 
demonstrate that indeed CREB, but not CREB phosphorylation, is necessary for several 
learning and memory behaviors (i.e., fear conditioning and operant learning).  
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It is clear from our findings that fear conditioning induces CREB-mediated 
transcription, which is not seen in naïve controls exposed to no behavioral stimulus. 
Having shown that CREB Ser133 phosphorylation is not required to mediate 
transcriptional and behavioral changes in response to these stimuli, we postulate that 
alternative regulators of CREB transcription must exist that mediate these signaling 
events. For example, other post-translational modifications to CREB, such as 
glycosylation (Lamarre-Vincent and Hsieh-Wilson, 2003; Rexach et al., 2012) or 
phosphorylation at serine 142 may play a critical role in CREB-mediated gene 
transcription and/or behavioral response. Additionally, CREB-regulated transcriptional 
coactivators (CRTCs) represent a potential mechanism by which phosphorylation-
independent CREB-mediated gene transcription could occur (Fimia et al., 1999; Altarejos 
and Montminy, 2011).  
Mechanistically, chromatin immunoprecipitation assays determined that CREB 
binds to DNA regardless of phosphorylation at Ser133, similar to what has been seen in 
the liver (Everett et al., 2013), and both quantitative mRNA analysis of relevant CREB 
targets and global expression profiling demonstrated that hippocampal CREB-mediated 
transcription does not rely upon the Ser133 phosphorylation event as previously believed. 
However, the alterations in allelic frequency in offspring from heterozygous matings 
described above support a role for CREB phosphorylation in early mouse development, 
perhaps through its established role in cell survival (Bonni et al., 1999; Riccio et al., 
1999). Thus, while important biological processes require phosphorylation of CREB on 
Ser133, the data presented here indicate that memory consolidation is not one of them.  
The role of CREB in long-term memory storage has been an area of intense 
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investigation for over 20 yrs in a variety of systems, including Aplysia, Drosophila, and 
rodents. CREB is referred to as an “activity-dependent” transcription factor and the 
phosphorylation of Ser 133 has been the “activity” most closely associated with this 
protein, as it is easy to detect and occurs within minutes of neuronal stimulation 
(Gonzalez and Montminy, 1989). The novel mouse model presented here, which prevents 
phosphorylation of Ser 133, suggest a reevaluation of the reliance on Ser133 
phosphorylation as readout of CREB activation so prevalent in the field.  
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Appendix 1. Derivation and characterization of Ser133Ala mutant mouse. A, 
Schematic depicting the exon structure of the mouse Creb1 gene. Exon 7, encoding 
Ser133 (TCC), was replaced with a mutant sequence containing a Ser133Ala (TCC to 
GCC) substitution along with a self-excising selection cassette. Testes-specific 
expression of Cre recombinase, driven by the tACE promoter, resulted in deletion of the 
selection cassette and establishment of the CREBS133A allele upon germline transmission. 
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The Pro132 codon was also changed from CCT to CCC, maintaining the Pro residue but 
abolishing the StuI restriction enzyme site. B, Sequence of the PCR product confirms the 
presence of the Ser133Ala mutation. C-D, Western blot analysis demonstrates that 
hippocampal pCREB immunoreactivity is not present in S133A mutant mice. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as loading control. (***)  
P < 0.001. E, Western blot analysis demonstrates that hippocampal CREB 
immunoreactivity is normal in Ser133Ala mutant mice, as compared with CREBαΔ 
mutant mice. (***) P < 0.001. F, Unlike the increase seen in CREBαΔ mutant mice, 
Ser133Ala homozygous mutant mice exhibited normal levels of CREM mRNA in the 
hippocampus, as determined by RT-PCR and normalized to the housekeeping gene TBP. 
(***) P < 0.001 compared with wild type. G, There was a corresponding increase in 
ICER mRNA, the main CREM isoform, in the hippocampus of CREBαΔ mutant mice, 
but no differences were seen between Ser133Ala and wild-type mice. (***) P < 0.001 
compared with wild type. H, Analysis of 473 offspring revealed a decrease in the 
proportion of mice homozygous for the S133A mutation compared with expected 
Mendelian frequencies.  
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Appendix 2. S133A mice exhibit normal aversive and instrumental learning. A, 
Ser133Ala mutant mice do not exhibit alterations in shock sensitivity when exposed to 
increasing shock intensities (FGENOTYPE (1,18) = 0.078, P = 0.78). B, Ser133Ala mutant 
mice exhibited similar levels of freezing during the 5-min fear conditioning training day 
(FGENOTYPE (1,33) = 0.872, P = 0.36). C, When placed back in the conditioning context, 
Ser133Ala mice showed normal levels of freezing compared with wild-type mice t(16) = 
0.52, P = 0.61, N = 9). D, Ser133Ala mice also displayed normal levels of freezing 
during presentation of the conditioned stimulus CS; t(15) = 0.60, P = 0.56). E, CREBαΔ 
mutant mice display a decrease in the ability to discriminate between the rewarded 
response and the unrewarded one in an instrumental learning task (F(3,96) = 11.80, P < 
0.0001 for the CREBαΔ mutant mice), whereas Ser133Ala mutant mice do not exhibit 
impaired instrumental learning. (***) P < 0.001 compared with all three other groups.  
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Appendix 3. Ser133Ala mice exhibit normal levels of CREB-binding and gene 
transcription. Chromatin immunoprecipitation revealed normal levels of CREB 
enrichment at the cfos (A) F(2,13) = 49.01, P < 0.0001; S133WT, S133A Mutant versus 
Control, P < 0.0001; S133WT versus S133A Mutant, NS) and fosB (B) F(2,13) = 22.38, P 
< 0.0001; S133WT, S133A Mutant versus Control, P < 0.01; S133WT versus S133A 
Mutant, NS) promoter regions, with no significant differences between Ser133Ala mice 
and controls. Normal levels of HK3K4me3 enrichment at the cfos (C) F(2,13) = 15.32, P < 
0.0009; S133WT, S133A Mutant versus Control, P < 0.01; S133WT versus S133A 
Mutant, NS) and fosB (D) F(2,13) = 21.40, P = 0.0004; S133WT, S133A Mutant versus 
IgG WT S133A 
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Control, P < 0.01; S133WT versus S133A Mutant, NS) promoter in Ser133Ala mutant 
mice indicate a transcriptionally permissive state. Fear conditioning leads to a significant 
increase in Nr4a1 (E) N = 5-8, FINTERACTION (3,42) = 6.056, P = 0.0016, S133 WT, S133A 
Mutant, CREBαΔ Fear versus Control, P < 0.001; CREBαΔ versus Control, NS), Nr4a2 
(F) N = 5-8; FINTERACTION (3,44) = 9.566, P < 0.0001, S133 WT, S133A Mutant, CREBαΔ 
Fear versus Control, P < 0.0001; CREBαΔ versus Control, NS), and cfos (G) N = 5-8; 
FINTERACTION (3,44) = 5.87, P = 0.006, S133 WT, S133A Mutant, CREBαΔ Fear versus 
Control, P < 0.0001; CREBαΔ versus Control, NS) hippocampal gene expression in both 
wild-type and Ser133Ala mice but not CREBαΔ mutant mice. (**) P < 0.01, (***) P < 
0.001 compared with tissue taken from naïve controls. Global expression profiling of 
hippocampal lysates from S133A versus wild-type mice revealed no significant al- 
terations in any individual gene on the microarray (H).  
 
 
 
 
Appendix Table 1. Primers used for qRT-PCR analysis  
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